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Abstract 
AMPK-HDAC5 Pathway Facilitates Nuclear Accumulation of HIF-1α and Functional 
Activation of HIF-1 by Deacetylating Hsp70 in the Cytosol 
Shuyang Chen 
Advisor: Nianli Sang, Ph.D. 
 
Hypoxia-inducible factor 1 (HIF-1) is a major transcriptional regulator of adaptation to 
hypoxia at both cellular and tissue levels. As such, HIF-1 plays an important role in the 
pathogenesis of cancer and ischemic disorders including heart disease and cerebral 
ischemia. The expression of HIF-1α, the functional determining subunit of HIF-1 
increases in the majority of cancers, and up-regulation of HIF-1α is associated with 
increased risk of mortality in a variety of cancer types. Therefore HIF-1 is a potential 
target for the treatment of both cancer and ischemic disorders. Accumulating evidence 
suggests that histone deacetylase (HDAC) activity is critical for HIF-1α stability and 
HIF-1 activation. However, the underlying mechanism remains unclear.  
In this thesis, I demonstrate that the cytosolic HDAC5 increases HIF-1α stability by 
deacetylating heat shock protein-70kD (Hsp70). Specifically, HDAC knockdown 
screening revealed that only knockdown of HDAC5 impairs hypoxic HIF-1α 
accumulation and HIF-1 activity (Chapter 2 and Chapter3). Overexpression of cytosol-
localized and enzymatic active HDAC5 stabilizes HIF-1α and promotes HIF-1 function 
(Chapter 4 and Chapter 5). To identify the cytosolic substrate of HDAC5 that is 
responsible for HIF-1α stabilization, I knocked down HDAC5, and examined the 
acetylation statue of HIF-1α, Hsp70 and Hsp90. I found that only the acetylation level of 
x 
 
Hsp70 was increased by HDAC5 knockdown. Moreover, hyperacetylatation of Hsp70 led 
to accelerated degradation of HIF-1α and poor nuclear accumulation of HIF-1α. I further 
show that AMPK-triggered cytosolic translocation of HDAC5, which facilitated HIF-1α 
stabilization and promoted cell survival under stressful conditions (Chapter 7).  Finally, I 
show an HDAC5 inhibitor, LMK235, disrupted the nuclear accumulation of HIF-1α and 
tumor cell proliferation under hypoxic conditions. Taken together, my findings 
demonstrate that the HDAC5-induced deacetylation of Hsp70 facilitates a rapid nuclear 
accumulation of HIF-1α, indicating that AMPK-induced cytosolic translocation of 
HDAC5 plays an active role in cells’ energy homeostasis during hypoxia and ischemia 
associated nutrient insufficiency. 
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Chapter 1: Background 
1. Introduction	
Cardiovascular disease and cancer are the top two leading causes of death in United 
States. By 2014, cardiovascular disease announces almost 1 of every 3 deaths (Go, 
Mozaffarian et al. 2014). Only exceeded by cardiovascular disease, cancer accounts 
nearly  1 of every 4 deaths in United States (Society 2014). How to improve the 
prevention and treatment of these two classes of diseases remains an unfinished task.  
Both cardiovascular disease and cancer are frequently associated with hypoxia (Chen 
and Sang 2011).  Hypoxia is a condition in which the tissue is deprived of sufficient 
oxygen (O2) supply, which is required for energy metabolism and other oxidation 
processes for all metazoan species including human. Particularly, both mammalian 
heart and brain are obligate aerobic organs, and the heart consumes approximately 
8~15 ml O2/min per 100 gram tissue at resting pulse rate, which is about 5 times more 
than the brain (Giordano 2005). Although the causes of cardiovascular disease are 
complicated and diverse, insufficient blood flow accompanied by limited O2 
availability to organs is always the most important contributing factor to the 
pathological processes and prognosis. In solid tumors, accelerated cancer cell 
proliferation and metabolic transformation increase the demand for O2. Defects in 
tumor vascular structure limit the O2 availability in certain regions within solid tumor 
tissue (Figure 1-1).   
Hypoxia inducible factor-1 (HIF-1) is the major transcription factor which regulates 
the adaptation to hypoxia at both cellular and tissue levels. HIF-1 activation 
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reprograms gene expression and cellular energy metabolism, facilitating cell survival 
under transient hypoxic condition. It also transcriptionally stimulate the generation 
and secretion of  pro-angiogenic factors and expression of their receptors, thus 
promoting tissue angiogenesis (Semenza 1999, Semenza 2000, Bel Aiba and Gorlach 
2003, Huang, Hickey et al. 2004, Pajusola, Kunnapuu et al. 2005, Egger, Schgoer et 
al. 2007, Gao, Ferguson et al. 2007, Pirkmajer, Filipovic et al. 2010, Xue, Cai et al. 
2010, Dragu, Schnurer et al. 2011, Tekin, Dursun et al. 2011). As such, hypoxia and 
HIF-1 activation have been considered to play important roles for normal tissue 
adaptation to hypoxia, and found to correlate with poor prognosis of tumors. 
Evidence showed that the risk of mortality is increased in patients whose primary 
tumors are poorly oxygenated (pO2 <10 mmHg) (Vaupel 2009). Accordingly, HIF-1 
is potentially an important therapeutic target for both cardiovascular disease and 
cancer. 
This chapter attempts to outline the current knowledge of HIF-1, focusing on its role 
in oxygen sensing, normal tissue adaptation to hypoxia and tumor progression. The 
traditional regulatory pathways of HIF-1α will be introduced. Particularly, I will 
summarize the findings that HDACIs repress HIF-1 function. Finally, I will present 
my hypothesis and rationale of this thesis study, which is aimed to a better 
understanding of the mechanisms underlying HDACI-induced repression of HIF-1, 
and a physiological role of HIF-1 in energy homeostasis in cells. 
2. Hypoxia-inducible factors 
Hypoxia-inducible factors (HIF) are a transcription factor family consisting of HIF-1, 
HIF-2 and HIF-3.  They are all heterodimers composed of a unique α-subunit (HIF-1α, 
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2α or 3α) and a shared β-subunit (HIF-β), which is also known as ARNT (Aryl 
hydrocarbon receptor nuclear translocator). HIF-1 and HIF-2 are the two major 
contributors to the transcription of HIF target genes, as HIF-1 is expressed 
ubiquitously in all tissues and HIF-2 is differentially expressed in various tissues 
(Semenza 1999, Semenza 2000). HIF-3 lacks a transactivation domain (without 
transcriptional activity) and is proposed to act as a dominant-negative regulator of 
HIF-1 and HIF-2 (Maynard, Evans et al. 2005). Even though their downstream target 
genes are mostly overlapping, HIF-1 and HIF-2 have already been shown to have 
distinctive, non-redundant functions (Hu, Wang et al. 2003, Carroll and Ashcroft 
2006, Hu, Sataur et al. 2007). The general physiological effects of overexpressing 
HIF target genes is to promote the uptake and utilization of O2 and other nutrients, 
thus building a new O2 homeostasis in the tissue and adjust its adaption to hypoxia 
(Semenza 1999, Semenza 2000). At tissue level, several key angiogenesis factors, 
such as endothelial growth factor (VEGF) (Kaelin 2007, Liao and Johnson 2007), 
basic fibroblast growth factor (bFGF) and their receptors (Bos, van Diest et al. 2005, 
Calvani, Rapisarda et al. 2006), are stimulated upon HIF-1 activation. The expression 
of these growth factors and receptors promotes endothelial proliferation, migration 
and differentiation, leading to tissue vascularization during development, wound 
healing, adaptation to chronic ischemic lesion, and pathological angiogenesis during 
tumor progression.  
Structurally, HIF is a basic helix-loop-helix (bHLH) transcription factor which 
belongs to the PER-ARNT-SIM (PAS) subfamily. HIF-1α, HIF-2α and HIF-β are 
structurally similar, each containing a bHLH domain for DNA binding, a PAS 
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domain for hetero-dimerization and transactivation domain for transcriptional activity 
regulation (Semenza 2003) (Figure 1-2). As the HIF-β subunit is constitutively 
expressed to serve as a common dimerization partner for the formation of multiple 
transcription factors, the α subunits (HIF-1α and HIF-2α) determine the 
transactivation activity of HIF-1 and HIF-2.  
HIF-1α is regulated by two well-known O2 sensing mechanisms (Lando, Gorman et al. 
2003, Semenza 2004, Kaelin 2005) (Figure 1-2, 3). The first mechanism is HIF-α 
protein is rapidly degraded by proteasome in the presence of adequate O2 through a 
hydroxylation-dependent ubiquitination process. The prolyl hydroxylase (PHD) 
hydroxylates HIF-1α at two prolyl residues (P402 and P564) in the presence of O2 
(Lando, Gorman et al. 2003, Semenza 2004, Kaelin 2005). Hydroxylated HIF-1α is 
then recognized by VHL for ubiquitination and is finally degraded by 26S proteasome 
(Salceda and Caro 1997, Huang, Gu et al. 1998). The second mechanism is that HIF-
1α transcriptional activity is regulated by its transactivation potential (TAP) which is 
affected by the interaction with co-activator p300/CBP(Lando, Peet et al. 2002, Sang, 
Fang et al. 2002). Factor inhibiting HIF-1 (FIH), another O2-dependent hydroxylase, 
modifies the Asn residue (N803) in the carboxyl terminal activation domain (HIF-1α 
C-TAD) and disrupts its interaction with p300/CBP (Lando, Peet et al. 2002, Sang, 
Fang et al. 2002). Lack of O2 reduces the activity of these hydroxylases and activates 
HIF function (Lando, Gorman et al. 2003, Semenza 2004, Kaelin 2005). The O2-
dependent hydroxylation of HIF-1 forms the biochemical basis for the conventional 
O2 sensing pathway (Figure 1-3), representing the initiation of a physiological 
adaptation to hypoxia. 
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HIF-1- enhanced glucose metabolism is critical for cell survival and proliferation 
under hypoxic condition. Carbonic anhydrase 9 (CA-IX), glucose transporter 1 
(GLUT1) and lactate dehydrogenase (LDH) are three well-known metabolic enzymes 
which are majorly regulated by HIF-1 activity and they are widely used as cellular 
biomarkers for hypoxia and HIF-1 function (Semenza 2003). GLUT1 increases 
glucose uptake to enhance energy production; LDH catalyzes pyruvate into lactate 
and the enhanced LDH activity effectively converts NADH to NAD+, facilitating 
glycolysis to continue under hypoxic condition. CA-IX catalyzes the reversible 
hydration of carbon dioxide, which facilitates the neutralization of exceeded lactate 
inside the cells (Figure 1-5). Several other glycolytic genes are also stimulated by 
HIF-1, such as hexokinase 2 (HK2), phosphofructokinase 2 (PFK2), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and pyruvate kinase 2 (PK2) (Semenza 2003).   
As HIF-1 function is essential for the control of cellular energy metabolism, whether 
the cellular energy sensor, AMP-activated protein kinase (AMPK), functionally 
interacts with HIF-1 remains unclear. AMPK is a highly conserved serine or 
threonine kinase, and is a master regulator of cellular energy homeostasis (Winder 
and Hardie 1999).  AMPK is allosterically activated by AMP associated with ATP 
shortage. AMPK is a heterotrimeric enzyme consists of α, β, and γ subunits. The 
AMPK-γ is the subunit that provides AMPK its ability to sensitively detect the 
cellular AMP level. Binding of AMP to AMPK-γ subunit exposes the catalytic 
domain on AMPK-α, thus activates AMPK (Adams, Chen et al. 2004). A cascade of 
AMPK triggered events eventually inhibit ATP-consuming anabolic processes but 
stimulate ATP producing catabolic processes. (Lage, Dieguez et al. 2008). The 
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activation of AMPK by hypoxia has been reported (Laderoute, Amin et al. 2006, Jibb 
and Richards 2008, Mungai, Waypa et al. 2011). One study showed that AMPK 
activates HIF-1 in prostate cancer cells (Lee, Hwang et al. 2003). On the other hand, 
AMPK is also reported to repress HIF-1α translation through inhibiting mTOR 
signaling pathway (Shackelford and Shaw 2009). However, whether and how AMPK 
affects HIF-1α stabilization and HIF-1 activation remain unclear.  
3. Physiological roles of HIF-1 in normal tissues 
Tissue hypoxia commonly occurs as a consequence of cardiovascular disorders. The 
cardiovascular function is required to deliver O2 and other nutrients to cells of the 
whole body. Cardiovascular disorder is the top cause of death in United States and 
other developed countries, which counts almost 1/3 of all deaths updated to 2014 (Go, 
Mozaffarian et al. 2014), and the eventual direct cause of death is usually brain death 
caused by brain hypoxia. Brain is one of the most sensitive tissues to O2 availability. 
Brain cells begin to die about 5 min after lack of O2 supply (Gisvold and Safar 1982). 
Furthermore, O2 is also indispensable for the heart to maintain its contractibility and 
other function. Normally the heart consumes approximately 8~15 ml O2/min per 100 
gram tissue at resting pulse rate, 5 times more O2 than the brain does (Giordano 2005). 
Coronary artery insufficient may limit O2 supply to cardiac muscle, and O2 supply 
may completely deprived in more severe cases, such as heart infarction. As a 
transcription factor, HIF-1 is able to adjust gene expression in heart to ensuring 
normal cardiac function and viability in response to stressful signals such as high O2 
consumption (e.g., pressure overload) or poor O2 delivery (e.g., coronary artery 
disease). HIF-1 alters gene transcription and increases the level of angiogenesis, 
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cardiovascular remodeling, erythropoiesis and glucose metabolism under hypoxia 
condition. Moreover, HIF-1 is also required to maintain redox homeostasis, energy 
metabolism, vascularization, calcium flux and contractile function under normoxic 
condition (Huang, Hickey et al. 2004). Therefore, generally, HIF-1 activation may 
play an important protective role in a variety of conditions associated with ischemic 
disorders.  
Several animal studies showed HIF-1 function is critical for ischemia-induced 
vascular remodeling (Rivard, Fabre et al. 1999, Patel, Kimura et al. 2005, Bosch-
Marce, Okuyama et al. 2007, Rey, Lee et al. 2009, Rey, Luo et al. 2011).  At every 
age, HIF1α +/- mice (HIF1α -/- is lethal) showed reduced blood flow recovery and 
increased tissue damage after femoral artery ligation compared with WT littermates 
(Bosch-Marce, Okuyama et al. 2007). Injection of AdCA5, a constitutively active 
form of HIF-1α, intramuscularly into 8 month old mice was enough to protect the 
mice from age dependent impairment of ischemia induced vascular remodeling 
(Bosch-Marce, Okuyama et al. 2007). Injection of AdCA5 could also improve the 
recovery of blood flow by increasing the luminal diameter of vessels in rabbit model 
(Patel, Kimura et al. 2005). These animal studies suggest the significant role of HIF-
1α in vascular remodeling and future prospects of AdCA5 therapy in clinical trials.  
Ischemic preconditioning (IPC) is an experimental technique to protect the tissue 
from loss of blood supply (Murry, Jennings et al. 1986). The IPC technique is to 
expose the heart to short periods of ischemia and reperfusion, thus it can protect the 
heart against a subsequent prolonged ischemic insult. The exact mechanism behind 
this phenomenon is not clear, however, many evidence suggest that HIF-1 mediates 
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the protection induced by IPC. The IPC stimulus could decrease the infarct size in the 
hearts from WT mice under a prolonged ischemia-reperfusion, but provide no 
protection in HIF-1α +/- mice (Cai, Zhong et al. 2008). Furthermore, a recent finding 
showed that when the hearts from WT mice were infused with acriflavine, a HIF-1α-
HIF-1β dimerization inhibitor, before IPC, the protection effect was blocked (Sarkar, 
Cai et al. 2012). HIF-1 may also protect against pressure overload heart failure. At 
early stage, hypertension result in a compensatory left ventricular hypertrophy to 
maintain the ejection fraction; however, eventually it will progress to an 
uncompensated state with a decreased ejection fraction and lead to heart failure (Levy, 
Garrison et al. 1990). Knockout of HIF-1α in cardiacmyocytes rapidly induced 
cardiac hypertrophy, and led to heart failure after 3 weeks of transaortic constriction, 
an experimental method to induce pressure overload (Sano, Minamino et al. 2007). 
Taken together, these findings suggest the protective role of HIF-1 in chronic 
ischemic disease.  
It is worthy to note that HIF-1 activation may also contribute to the pathological 
processes in end-stage heart failure. HIF-1 not only  increases the level of 
angiogenesis and cardiovascular remodeling, but also switches the energy production 
from oxidative phosphorylation to glycolytic metabolism, thus making the 
cardiacmyocytes do not have enough ATP to maintain normal cardiac function 
(Semenza 2003).  These features of HIF-1 could explain that why HIF-1α +/- mice 
may show either impaired (Silter, Kogler et al. 2010), or improved cardiac function 
(Krishnan, Suter et al. 2009) after transaortic constriction. These facts reflect the 
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complexity of HIF-1 activation on cardiac function, indicating a precise control of 
HIF-1 is critical to maintain normal cardiovascular function. 
4. HIF-1 activation in solid tumors 
Scientists have already revealed that HIF-1 function is the master regulator of 
angiogenesis, glucose metabolism and metastasis in cancer cells, which causes the 
therapy resistance (Jiang and Feng 2006, Daponte, Ioannou et al. 2008, Gomez-
Raposo, Mendiola et al. 2009). In addition, tumor hypoxia is frequently related to 
tumor resistance to radiation therapy and chemo therapy (Giaccia, Siim et al. 2003, 
Semenza 2003, Welsh and Powis 2003, Brown and Wilson 2004, Powis and 
Kirkpatrick 2004). So it is reasonable to target HIF-1 as part of cancer therapy 
(Schwartz, Bankson et al. 2010, Semenza 2010).  
HIF-1 activation and enhanced expression of HIF-1 target genes play key roles in 
angiogenesis, which is defined as the formation of new blood vessels from original 
existing vessels. Hypoxia and HIF-1 activation (e.g., overexpressed HIF-1 target 
genes and angiogenesis) has been observed in varieties of solid tumors (Zhong, 
Chiles et al. 2000, Semenza 2004, Semenza 2006, Vaupel, Hockel et al. 2007). 
Deletion of HIF-1α dramatically inhibits solid tumor development in vivo, and results 
in reduced pro-angiogenic factors, such as VEGF which majorly contributes to the 
formation of capillaries, and FGF-1 which primarily stimulates the formation arterial 
vessels (Ryan, Lo et al. 1998, Ryan, Poloni et al. 2000, Hirota and Semenza 2006). 
Basically, three components are involved in angiogenesis: the paracrine signaling 
molecules from tumor cells, the extracellular matrix and the endothelial response 
(Bouzin and Feron 2007). Moreover, the signaling molecules do not only promote 
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angiogenesis, they also facilitate the growth and proliferation of the tumor cells 
(autocrine). Therefore, HIF induced angiogenesis and expression of growth factors 
meets the needs of tumor development and progression. HIF-2α is more cell type 
specific and has been reported to be significant in endothelial cells, however, HIF-1α 
and HIF-2α have been observed in both endothelial and tumor cells (Hu, Wang et al. 
2003, Carroll and Ashcroft 2006, Licht, Muller-Holtkamp et al. 2006, Hu, Sataur et al. 
2007, Lofstedt, Fredlund et al. 2007). Generally HIF-1α is thought to play a more 
important role in tumor cells for to hypoxia (Ryan, Lo et al. 1998, Ryan, Poloni et al. 
2000, Hirota and Semenza 2006). 
HIF-1 activation is not only induced by hypoxia. In solid tumors, growth factors, 
mitogenic signaling (MAPK, PI3K/Akt), oncogenes (Ras and Myc) activation and 
loss of tumor suppressors (VHL, p53 and PTEN) activate HIF-1 by modifying 
different steps of the conventional HIF-1 regulation pathways (An, Kanekal et al. 
1998, Blagosklonny, An et al. 1998, Ravi, Mookerjee et al. 2000, Zundel, Schindler 
et al. 2000, Lando, Gorman et al. 2003, Sang, Stiehl et al. 2003, Semenza 2004, 
Isaacs, Jung et al. 2005, Kaelin 2005, Selak, Armour et al. 2005). Currently, scientists 
are actively exploring methods to directly target HIF-α for cancer therapy (Welsh, 
Williams et al. 2004, Kong, Park et al. 2005, Tan, de Noronha et al. 2005). 
Interestingly, several kinds of small molecular inhibitors, originally developed for 
cancer therapy but not designed to target HIF function, were demonstrated to showing 
anti-cancer effects with anti-angiogenesis features. These compounds include 
HDACIs (Marks, Richon et al. 2001, Johnstone and Licht 2003, Drummond, Noble et 
al. 2005), Hsp90 inhibitors (Miyata 2005, Neckers and Neckers 2005), proteasome 
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inhibitors (Sunwoo, Chen et al. 2001, Bazzaro, Lee et al. 2006, Joazeiro, Anderson et 
al. 2006, Ishii, Waxman et al. 2007) and microtubule inhibitors (Mabjeesh, Escuin et 
al. 2003, Escuin, Kline et al. 2005, Newcomb, Lukyanov et al. 2006). Even though 
these compounds are targeting different biological targets, studies have showed that 
their anti-angiogenic and anti-tumor effects may contributed by HIF-1 inactivation. 
The well-known conventional O2 dependent regulatory mechanism of HIF-1 provides 
us many strategies to target HIF-1 as a novel therapy. Recently, there are several HIF-
1 activators have been identified and they are potentially beneficial for anemia 
patients. There are also several HIF-1 inhibitors have been identified by compound 
screening for cancer therapy (Welsh, Williams et al. 2004, Kong, Park et al. 2005, 
Tan, de Noronha et al. 2005). Interestingly and surprisingly, both basic science and 
clinical trial researchers have observed that histone deacetylase inhibitors (HDACIs) 
block HIF function such as angiogenesis and suppress tumor progression (Marks, 
Richon et al. 2001, Johnstone and Licht 2003, Drummond, Noble et al. 2005). It is 
unknown at the beginning that why and how HIF function is disrupted by HDACIs. It 
has been reported that HDACIs could repress the transcriptional activity of both HIF-
1 and HIF-2 in specific tissues (Fath, Kong et al. 2006). More importantly, a 
ubiquitous mechanism has been indicated as scientists verified that HDACIs repress 
HIF-α subunit in all cells examined (Fath, Kong et al. 2006, Kong, Lin et al. 2006). 
However, since the effects of HDACIs are generally pleiotropic and HDACIs were 
originally designed to target histone acetylation for epigenetic therapy, the 
biochemical and biological mechanisms underlying these pharmacologic effects 
remain elusive. 
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5. Histone Deacetylase inhibitors in cancer therapy 
Histone Deacetylases (HDACs) define a large family of enzymes which remove 
acetyl groups from N-ε-lysines (Ahringer 2000, Yang and Seto 2003, Yang and 
Gregoire 2005). Since the original discovery of acetyl-histones as HDAC substrates, 
more non-histone substrates of HDAC such as transcription factors or co-activators 
have been discovered showing the same modification (Table 1-1). Therefore, HDAC 
is now re-defined as lysine deacetylase, to more precisely reflect the fact that its 
substrate acetyl-lysine, not exclusive to histone (Choudhary, Kumar et al. 2009). The 
acetylation statuses of these proteins are usually reversibly regulated by a dynamic 
balance between HDACs and Histone Acetyl-Transferases (HATs). 
So far 18 human HDACs have been identified, and they are classified into four 
classes based on their homology to yeast (Saccharomyces cerevisiae) histone 
deacetylases (Blander and Guarente 2004, Bali, Pranpat et al. 2005, Marks and 
Dokmanovic 2005) (Table 1-2). HDAC1, HDAC2, HDAC3 and HDAC8, which are 
majorly nuclear localized, defines the Class I HDACs. Generally, Class I HDACs are 
considered to be the major contributor to epigenetic modification, in which 
deacetylating histones and repressing gene expression, despite a few exceptions 
(Figure 1-5) (Rascle, Johnston et al. 2003, Joseph, Mudduluru et al. 2004). For 
examples, HDAC1 was also found to deacetylate PTEN, a phosphatase which is 
involved in cell signaling, and inhibit its function (Ikenoue, Inoki et al. 2008); 
HDAC3 was also reported to deacetylate p65, an subunit of NF-κB, which is a key 
transcription factor involved in responses to inflammation and other cell stresses 
(Hasselgren 2007). Class I HDACs are also commonly associated with transcription 
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repressive complexes known as Sin3, NuRD, CoRest (HDAC1, 2), and SMRT/NCoR 
(HDAC3) (Ahringer 2000, Yang and Seto 2003, Goodson, Jonas et al. 2005, Yang 
and Gregoire 2005, Rosenfeld, Lunyak et al. 2006). HDAC4, HDAC5, HDAC6, 
HDAC7, HDAC9 and HDAC10 define another large group of HDACs: Class II 
HDACs (Yang and Gregoire 2005). HDAC4 is involved in nuclear transcriptional co-
repressor complex and is implicated in myocyte differentiation, skeletogenesis and 
neuronal survival (Wang, Bertos et al. 1999, Miska, Langley et al. 2001, Vega, 
Matsuda et al. 2004, Chen and Cepko 2009); similar to HDAC4, HDAC5 also 
interacts with nuclear receptor co-repressor 1 and 2, which are important in the down 
regulation of DNA expression (Huang, Zhang et al. 2000), and regulates the 
development and pathophysiology of cardiomyocytes (Lemercier, Verdel et al. 2000, 
Vega, Harrison et al. 2004); as an exclusive member mainly functioning in cytosol, 
HDAC6 deacetylates cytoplasmic non-histone substrates such as Hsp90 (Bali, 
Pranpat et al. 2005, Kovacs, Murphy et al. 2005) and α-tubulin (Hubbert, Guardiola et 
al. 2002, Matsuyama, Shimazu et al. 2002, Haggarty, Koeller et al. 2003, Zhang, Li et 
al. 2003). HDAC6 also interacts with misfolded proteins and dynein motors, thus 
allowing misfolded proteins to be physically transported to proteasome for 
degradation (Rodriguez-Gonzalez, Lin et al. 2008). Both Class I and Class II HDACs 
are Zinc dependent, besides this,  Class III comprises of the NAD+ dependent Sirt1-7 
(North, Marshall et al. 2003, Inoue, Hiratsuka et al. 2007, Vaquero, Sternglanz et al. 
2007). HDAC11, the only one sometimes called Class IV HDAC (Gao, Cueto et al. 
2002), was reported to interact with HDAC6.  
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HDAC inhibitors (HDACI) encompass diverse small molecular compounds that 
inhibit Zinc dependent deacetylases as competitive inhibitor. Several HDACIs 
commonly used in laboratories or applied in medical treatment listed in Table 1-3.  In 
most cases, protein acetylation in vivo is reversibly regulated by a dynamic balance 
between HAT and HDAC (Ahringer 2000, Yang and Seto 2003, Yang and Gregoire 
2005), so treatment of HDACIs breaks the balance and induces hyper-acetylation of 
proteins, especially histones. Similar to enhancing HAT activity, HDACIs generally 
promote gene expression by elevating the acetylation status of histones, or some 
target transcription factors and co-activators. Most importantly, HDACIs are anti-
cancer compounds undergoing intensive investigation. Clinical and experimental data 
show that HDACIs repress tumor growth and induce apoptosis. Moreover, Vorinostat 
(SAHA) and FK228 have already been approved by FDA for the treatment of 
cutaneous T cell lymphoma (CTCL) (Mie Lee, Kim et al. 2003, Sasakawa, Naoe et al. 
2003).  While the major effects of HDACIs have been considered as epigenetic 
therapeutics, HDACIs also enhance the level of acetylation of non-histone substrate 
and enhance or repress their activity as well. For example, the acetylation status of 
ACTR, c-Myb, E2F1, EKLF, FEN1, GATA, HNF-4,  Ku70, NF-κB, PCNA, p53, RB, 
Runx, SF1 Sp3, STAT, TFIIE, TCF and YY1 etc are affected by HDACIs 
(Drummond, Noble et al. 2005, Yang and Seto 2007).  
6. HDACIs repress HIF-1α stability and HIF-1 function 
Accumulating evidence suggests that HDAC inhibition represses HIF function in 
tumor cells (Kim, Kwon et al. 2001, Mie Lee, Kim et al. 2003, Sasakawa, Naoe et al. 
2003, Zgouras, Wachtershauser et al. 2003, Kato, Tamamizu-Kato et al. 2004, 
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Maltepe, Krampitz et al. 2005, Fath, Kong et al. 2006, Kong, Lin et al. 2006, Qian, 
Kachhap et al. 2006). The HDACIs showing anti-HIF activity generally block Zinc 
dependent Class I and Class II HDACs as competitive inhibitors. These HDACIs, 
while most are not specific for a particular HDAC, do not repress the enzymatic 
activity of Class III HDACs (NAD+ dependent, SIR2 family) (North, Marshall et al. 
2003, Inoue, Hiratsuka et al. 2007, Vaquero, Sternglanz et al. 2007). Trichostatin A 
(TSA) is widely used in laboratories among the early HDACIs and reported to repress 
angiogenesis both in vitro and in vivo (Kim, Kwon et al. 2001, Jeong, Bae et al. 2002). 
Other HDACIs including FK228 (Mie Lee, Kim et al. 2003, Sasakawa, Naoe et al. 
2003), butyrate (Zgouras, Wachtershauser et al. 2003, Joseph, Mudduluru et al. 2004), 
and LAQ82481 were also found to repress angiogenesis and the pro-angiogenic 
factors regulated by HIF, such as vascular endothelial growth factor (VEGF). 
Although HIF-1 had been generally accepted as a master regulator of angiogenesis, 
the early explanation for the anti-angiogenesis effects of HDACIs varied.  HDACIs 
may have a pleiotropic nature and a multiple pathway affected by HDACIs could 
possibly regulate angiogenesis.  
Later, evidence emerged that HDACI mediated repression of angiogenesis involves 
its suppressive effect on HIF-1 function (Kim, Kwon et al. 2001, Jeong, Bae et al. 
2002, Mie Lee, Kim et al. 2003, Kim, Kim et al. 2007, Li, Yuan et al. 2008, Manabe, 
Nasu et al. 2008). Subsequently, various mechanisms were reported including: 1. 
HDACI destabilize HIF-1α protein (Ahringer 2000, Kim, Kwon et al. 2001, Gao, 
Cueto et al. 2002, Hubbert, Guardiola et al. 2002, Jeong, Bae et al. 2002, Matsuyama, 
Shimazu et al. 2002, Haggarty, Koeller et al. 2003, North, Marshall et al. 2003, 
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Rascle, Johnston et al. 2003, Yang and Seto 2003, Zhang, Li et al. 2003, Joseph, 
Mudduluru et al. 2004, Demidenko, Rapisarda et al. 2005, Goodson, Jonas et al. 2005, 
Yang and Gregoire 2005, Kong, Lin et al. 2006, Qian, Kachhap et al. 2006, Rosenfeld, 
Lunyak et al. 2006, Inoue, Hiratsuka et al. 2007, Vaquero, Sternglanz et al. 2007); 2. 
HDACI directly repress HIF-1 transactivation potential (TAP) (Kasper, Boussouar et 
al. 2005, Fath, Kong et al. 2006); 3. HDACIs repress HIF-1 DNA binding affinity 
(Mie Lee, Kim et al. 2003); and 4. HDACIs inhibit HIF-1α nuclear translocation 
(Zgouras, Wachtershauser et al. 2003, Kato, Tamamizu-Kato et al. 2004). The 
HDACI mediated destabilization of HIF-1α and HDACI mediated repression of the 
HIF-1 TAP are two of the best supported models.  
A role of HDAC7 in regulating HIF-1 function was first proposed, based on its 
interaction with HIF-1α, and HDAC7 was found to increase the transactivation 
activity of HIF-1;  thus HDAC7 was thought to be a transactivation co-activator of 
HIF-1 (Kato, Tamamizu-Kato et al. 2004). An later report showed HDACIs repress 
the TAP of the carboxyl-transactivation domain (CAD) in both HIF-1α and HIF-2α 
(Fath, Kong et al. 2006). Importantly, low doses of HDACI were not sufficient to 
cause HIF-1α degradation but were able to repress HIF-1 TAP under both normoxic 
and hypoxic conditions (Fath, Kong et al. 2006). In addition, even though HDACIs 
repress TAP of both HIF-1α and HIF-2α, HDACIs only trigger the destabilization of 
HIF-1α, not HIF-2α (Fath, Kong et al. 2006). Their observations suggest that HDACI 
may cause HIF-1α loss of activity prior to degradation. Scientifically, this is also 
interesting because it shows HIF-α is unique compared to other transcription factors. 
Reports also showed that HDACIs represses HIF function by directly acetylating 
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p300/CBP, the important co-activators for HIF complexes (Stiehl, Fath et al. 2007, 
Black, Mosley et al. 2008). The acetyl-transferase p300/CBP possesses multiple 
domains that function as docking sites for transcription factors to bind including HIF-
1α. Interestingly, all those binding domains are lysine-rich, and have been shown 
subjective to auto-acetylating by p300/CBP (Stiehl, Fath et al. 2007, Black, Mosley et 
al. 2008). Importantly, exposure of cells to HDACIs causes hyperacetylation of 
p300/CBP and decreases their interactions with HIF-1α (Stiehl, Fath et al. 2007). 
These observations suggest that HDACIs may repress HIF function by affecting the 
acetylation status of HIF-α co-activator p300/CBP.  
Direct acetylation of HIF-1α was previously proposed. Early study by Kim’s group 
reported that a shorter mouse variant isoform mARD1 which is orthologous to yeast 
N-α-acetylase, catalyzes N-ε-acetylation of HIF-1α ODD at Lys532, thus promoting 
HIF-1α recognition and ubiquitination by VHL (Jeong, Bae et al. 2002). The longer 
human hARD1 isoform was also found to interact with HIF-1α ODD in vitro and 
with full length HIF-1α in vivo (Arnesen, Kong et al. 2005). Subsequent evidence has 
shown that hARD1 cannot acetylate human HIF-1α (Arnesen, Kong et al. 2005, 
Bilton, Mazure et al. 2005, Fisher, Des Etages et al. 2005, Murray-Rust, Oldham et al. 
2006). In addition, siRNA silencing of hARD1 showed no effects on HIF-1α stability 
(Bilton, Mazure et al. 2005, Fisher, Des Etages et al. 2005). Therefore, a precise role 
of ARD1 in HIF-1α stability is not clear.  
Class II HDACs have been proposed to regulate HIF-1α stability (Qian, Kachhap et al. 
2006). It is showed that HDAC4 and HDAC6 co-immunoprecipitate with HIF-1α and 
the specific inhibition of HDAC4 and HDAC6 repress HIF-1α stability (Qian, 
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Kachhap et al. 2006). It is possible that a multiple deacetylases regulation system 
could be involved in HDACI-induced repression of HIF-1 function. 
In the original model proposed by Kim’s group, acetylation of HIF-1α catalyzed by 
mARD1 or induced by HDACIs, is able to promote HIF-1α recognition and 
ubiquitination by VHL and eventual degradation. Since HDACIs enhance the 
interaction between HIF-1α and Hsp70, an alternative ubiquitination pathway 
mediated by Hsp70-associated CHIP has also been proposed (Luo, Zhong et al. 2010). 
Since most of the protein degradation cases triggered by a variety agents were 
observed in cells with normal ubiquitination system. So even the proteins subjective 
to the drug-induced degradation are generally ubiquitination associated, there is no 
direct evidence to support the absolute requirement of ubiquitination for such 
degradation.  
The ubiquitination process sequentially involves three enzyme activities: the E1 
ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzymes and the E3 
ubiquitin ligases. There is an only single E1 in mammalian cells but varieties of E3, 
such as VHL is a HIF-α specific E3 ligase. Accordingly, VHL defective cells or E1 
inactivated cells are not able to induce HIF-1α degradation and high level of HIF-α is 
accumulated. If HDACIs trigger HIF-1α degradation by ubiquitination pathway, the 
process should be dependent on functional E1 and VHL activity. In fact, it is reported 
that HDACIs decreased HIF-1α level in VHL (−/−) C2 and RCC4 cells, indicating 
that HDACIs possibly induce HIF-1α degradation through a mechanism existing in 
all tumors including those VHL negative tumors (Kong, Lin et al. 2006). In a special 
cell line TS20 which contains a temperature sensitive E1 (Lao, Chen et al. 2012), 
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inactivating E1 by culturing the cells at 39°C resulted in accumulation of non-
ubiquitinated HIF-1α, and apparently HDACIs are able to trigger degradation of these 
non-ubiquitinated HIF-1α (Kong, Lin et al. 2006). Based on these facts, it is suggest 
that HDACIs induce HIF-1α degradation by an ubiquitination-independent 
mechanism, whereas the precise mechanism remains to be dissected. 
7. Molecular chaperones and HIF-1α stabilization 
It has been reported by independent labs that molecular chaperones including Hsp70 
and Hsp90 directly interact with HIF-1α, suggesting HIF-1α is one of the client 
proteins of the Hsp70/Hsp90 machinery (Goetz, Toft et al. 2003, Miyata 2005, Kong, 
Lin et al. 2006). This model is well supported by the findings that the Hsp90 inhibitor 
17-AGG triggers ubiquitination-independent degradation of HIF-1α (Fath, Kong et al. 
2006, Kong, Lin et al. 2006). The folding of newly synthesized nascent HIF-1α to 
active conformation and translocation to nuclei requires the action of several 
molecular chaperones, including heat shock protein 70 kD and 90 kD (Hsp70 and 
Hsp90). It was proposed that the monomeric Hsp70 recognizes short hydrophobic 
motifs in HIF-1α, which are commonly exposed in nascent polypeptide chains 
(Buchner 1999). The newly synthesized HIF-1α associates with Hsp70 to form an 
early complex, leading to the delivery of HIF-1α to Hsp90 and form the mature 
complex (Taipale, Jarosz et al. 2010). The Hsp90 oligomeric double ring structure 
encloses the entire nascent HIF-1α and ensures the correct folding process of HIF-1α 
(Figure 1-4).   
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8. Summary and proposed model 
Based on experimental evidence and published literatures, it is clear that the 
transcription complexes of HIF-1 require deacetylase activity for their transcriptional 
activity. It is also conclusive that HDACIs induce the degradation of HIF-1α through 
a proteasome-dependent pathway and this degradation may involve both 
ubiquitination-dependent and ubiquitination-independent mechanism. While it is 
conclusive that in addition to serving as epigenetic therapeutics, the HDACIs for 
Class I and Class II HDACs also repress HIF function, the underlying mechanisms 
remain far from clear. A better understanding of the mechanisms may be beneficial 
not only for better efficacy of cancer therapy, but also for prevention of side effects 
on normal organs. Particularly, given the large numbers of deacetylases and their 
important roles in transcriptional regulation, epigenetic programming, chromosomal 
remodeling and other cellular processes, it is possible that non-selectively inhibiting 
all deacetylases may cause unpredictable side effects. Considering HIF function is 
required for the maintenance of O2 and nutrient supply and for prevention of cell 
death under hypoxic conditions, global repression of HIF activity in the entire body, 
particularly for long-term therapy treatment, may affect chronic adaptation required 
for ischemic disorders. On the other hand, since HIF function and dysregulated 
expression of VEGF play roles in tissue damage caused by ischemia-reperfusion, 
HDACI-mediated repression of HIF may be proven to be beneficial for acute 
ischemia (Granger, Abdullah et al. 2008). This dissertation aims to investigate the 
exact mechanism of HDAC regulated HIF function and bring new insight into the 
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molecular and biochemical mechanisms underlying the anti-HIF and anti-angiogenic 
effects of HDACIs (Figure 1-6).  
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Figure 1-1 
 
Figure 1-1 Hypoxia and cancer 
In normal tissue, blood vessels are well organized to ensure the delivery of adequate 
O2 to every single cell; in cancer tissue, cancer cells proliferate faster than new blood 
vessels (angiogenesis), resulting in hypoxia. 
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Figure 1-2 
 
 
 
Figure 1-2 Schematic structure of HIF-1α 
HIF-1 is a heterodimeric basic helix-loop-helix (bHLH) transcription factor which 
belongs to the PER-ARNT-SIM (PAS) subfamily. HIF-α and HIF-β subunits are 
structurally similar and both contain a bHLH domain for DNA binding, a PAS 
domain for hetero-dimerization and transactivation domain (TAD) for transcriptional 
activity regulation. Specifically for HIF-1α, O2 regulates the hydroxylation of proline 
(P) residues 402 and 564 by prolyl-hydroxylases (PHDs). These two hydroxylated 
prolines are required for binding von-Hippel-Lindau (VHL), an E3 ubiquitin-protein 
ligase. Poly-ubiquitylated HIF-1α will be recognized and degraded by 26S 
proteasome. O2 also regulates the association between HIF-1α and its transcriptional 
co-activators, p300/CBP. Factor inhibiting HIF-1(FIH-1), another O2-dependent 
hydroxylase, hydroxylates asparagine (N) residue 803 in HIF-1α and disrupts the 
interaction between HIF-1α and p300/CBP, thus inhibiting HIF-1 transcriptional 
activity. 
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Figure 1-3 
 
 
Figure 1-3 O2-dependent degradation of HIF-1α 
Under normoxic condition, HIF-1α is rapidly hydroxylated and recognized by E3 
ligase VHL. Ubiquitinated HIF-1α is delivered to, and degraded by 26S proteasome. 
Under hypoxic condition, low O2 availability blocks the HIF-1α hydroxylation. Then 
HIF-α is able to enter the nucleus and interact with HIF-1β subunit and co-activators. 
Subsequently HIF-1 recognizes the hypoxia response element (HRE) in the 
chromosome and performs its transactivation activity. 
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Figure 1-4 
 
 
 
Figure 1-4 O2-independent degradation of HIF-1α 
Folding of newly synthesized nascent HIF-1α to its active conformation requires the 
function of several molecular chaperones, including Hsp70 and Hsp90. The newly 
synthesized HIF-1α associates with Hsp70 to form an early complex, leading to the 
delivery of HIF-1α to Hsp90 to form the matured complex. The matured HIF-1α-
Hsp90 complex ensures the correct folding of HIF-1α. 
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Figure 1-5 
 
Figure 1-5 HIF-1 target genes 
Carbonic anhydrase 9 (CA IX), glucose transporter 1 (GLUT1) and lactate 
dehydrogenase (LDH) are three prototype metabolic enzymes which are mainly 
regulated by HIF-1. GLUT1 increases glucose uptake to enhance energy production; 
LDH catalyzes pyruvate into lactate and the enhanced LDH activity could facilitate 
the stimulated cellular glycolysis under hypoxic condition; CA IX catalyzes the 
reversible hydration of carbon dioxide, which could facilitate the neutralization of 
exceeded lactate inside the cells. Several other glycolytic genes are also stimulated by 
HIF-1, such as hexokinase 2 (HK2), phosphofructokinase 2 (PFK2), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and pyruvate kinase 2 (PK2). 
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Figure 1-6 
 
 
 
 
Figure 1-6 HDACs deacetylate both histones and non-histones  
The substrates of HDAC could be either histones or non-histones. HDAC generally 
removes the acetyl group from lysines. HDAC may modify protein activity by 
directly deacetylating, or indirectly by regulating complex formation of the target 
protein.  
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Table 1-1 Non-histone substrates of HDACs 
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Table 1-2 Classification of HDACs  
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Table 1-3 Classification of HDAC inhibitors 
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Figure 1-7 
 
 
Figure 1-7 Working model that HDACs regulate HIF-1α stability  
The HDACIs induced degradation of HIF-1α is an ubiquitin-independent proteasomal 
pathway (UIPS). Previous report in Dr. Nianli Sang’s lab (Kong, etc, 2006, JBC) has 
demonstrated that HDACIs do not repress the de novo thesis of HIF-1α, or accelerate 
the degradation of mature HIF-1α. Therefore, my working model hypothesizes that 
the folding and maturation process of HIF-1α requires a HDAC activity. 
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Chapter 2: HDAC5 is required for HIF-1α stability 
1. Abstract 
O2 is the key element for energy production, and is delivered to every single cell by 
circulation system. However, in solid tumors, the cells often outgrow blood supply, 
which result in hypoxia and nutrient insufficiency. HIF-1 is a transcription factor 
induced by hypoxia, which is the master regulator of angiogenesis and cellular 
adaptation to hypoxia and other stresses. HIF-1 is functionally determined by its α 
subunit HIF-1α because HIF-1α is O2 sensitive but HIF-1β is constitutively expressed. 
HIF-1α is rapidly hydroxylated, then recognized by VHL, and eventually degraded by 
proteasome under normoxic condition. So the stability of HIF-1α is critical for HIF-1 
transcription activity. Previous findings suggested that HDAC activity is essential for 
HIF-1α stability and HIF-1 function. HDAC inhibitors, such as TSA and SAHA, 
showed ability to degrade HIF-1α protein and inhibits HIF-1 function. However, as 
those HDAC inhibitors generally inhibit both Class I and Class II HDACs, which 
HDAC and how the HDAC regulates HIF-1α stability remains unclear. I present data 
here to show knockdown of HDAC5 reduces HIF-1α protein level. Firstly, my data 
indicate only knockdown of HDAC5, a Class IIa HDAC, reduced HIF-1α protein 
level, while knockdown of other HDACs (HDAC1, HDAC3 and HDAC6) showed 
limited effect. Furthermore, knockdown of HDAC5 reduced HIF-1α protein level in 
all three types of cancer cell lines that had been tested. I further demonstrate that 
knockdown of HDAC5 induces hydroxylation independent proteasomal degradation 
of HIF-1α. Taken together, my data indicate HDAC5 is required for HIF-1α protein 
stabilization. 
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2. Introduction 
HIF-1 is one of the most important master transcription factors of tissue angiogenesis 
and cellular adaptation to hypoxia. O2 is the critical element for energy metabolism 
and cellular respiration for all aerobic lives. Hypoxia leads to an ATP shortage by 
directly disrupting the electron transport chain (ETC). Accordingly, tissue hypoxia is 
implicated in a variety of diseases including cancer and cardiovascular diseases. 
Particularly in cancer, the combination of vascular dysfunction and accelerated cancer 
cell proliferation results in hypoxia and accumulation of HIF-1, which contribute to 
resistance of radiation and chemotherapy (Giaccia, Siim et al. 2003, Semenza 2003, 
Welsh and Powis 2003, Brown and Wilson 2004, Powis and Kirkpatrick 2004, 
Schwartz, Bankson et al. 2010). These facts provide us the rationale to target tumor 
hypoxia and HIF-1 for cancer therapy. 
Accumulating evidence suggests that inhibition of HDAC activity triggers HIF-1α 
degradation and represses HIF function (Kim, Kwon et al. 2001, Mie Lee, Kim et al. 
2003, Sasakawa, Naoe et al. 2003, Zgouras, Wachtershauser et al. 2003, Kato, 
Tamamizu-Kato et al. 2004, Maltepe, Krampitz et al. 2005, Kong, Lin et al. 2006, 
Qian, Kachhap et al. 2006). The HDACIs that cause HIF-1α degradation and repress 
HIF-1 function commonly non-specifically block Zinc dependent Class I and Class II 
HDACs (North, Marshall et al. 2003, Inoue, Hiratsuka et al. 2007, Vaquero, 
Sternglanz et al. 2007). Trichostatin A (TSA) is among these HDACIs which were 
reported to repress angiogenesis both in vitro and in vivo (Kim, Kwon et al. 2001, 
Jeong, Bae et al. 2002). Specifically, previous paper in Dr. Nianli Sang’ lab reported 
that TSA induces hydroxylation independent proteasomal degradation of HIF-1α 
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(Kong, Lin et al. 2006), and it has been generally agreed that HDACIs destabilize 
HIF-1α and suppress HIF-1 function (Ahringer 2000, Kim, Kwon et al. 2001, Gao, 
Cueto et al. 2002, Hubbert, Guardiola et al. 2002, Jeong, Bae et al. 2002, Matsuyama, 
Shimazu et al. 2002, Haggarty, Koeller et al. 2003, North, Marshall et al. 2003, 
Rascle, Johnston et al. 2003, Yang and Seto 2003, Zhang, Li et al. 2003, Joseph, 
Mudduluru et al. 2004, Demidenko, Rapisarda et al. 2005, Goodson, Jonas et al. 2005, 
Yang and Gregoire 2005, Kong, Lin et al. 2006, Qian, Kachhap et al. 2006, Rosenfeld, 
Lunyak et al. 2006, Inoue, Hiratsuka et al. 2007, Vaquero, Sternglanz et al. 2007). 
However, as different HDAC family members may have distinctive functions, which 
specific member is involved, and how that specific HDAC regulates HIF-1α function 
remains unclear. 
My study here was designed to identify which specific HDAC member is involved in 
stabilizing HIF-1α. I performed an unbiased HDAC knockdown screening and 
discovered a member of Class IIa HDACs, HDAC5 plays crucial role in the 
stabilization HIF-1α. I further proved that overexpression of HDAC5 offset the 
inhibitory effect of TSA on HIF-1α. In addition, I found knockdown of HDAC5 
reduces HIF-1α in the same manner as TSA, which is hydroxylation independent 
proteasomal degradation. Finally my broad screening also indicates that knockdown 
of HDAC5 reduces HIF-1α in varieties of cancer cell lines, including Hep3B, HeLa 
and MCF7.    
3. Materials and methods 
Chemicals and Special Reagents 
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Common chemicals and solvents were purchased from either Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Tissue culture and 
transfection reagents were obtained from Life Technologies (Carlsbad, CA). TSA 
#P9971e was purchased from BioMol (Plymouth Meeting, PA).  
Plasmids and DNA Recombination 
All restriction enzymes and other enzymes needed for PCR and DNA recombination 
were purchased from Life Technologies, Thermo Fisher Scientific or La Roche 
(Indianapolis, IN). Vector pcDNA3.0 was purchased from Life Technologies, and 
pcDNA3.0 n-flag was constructed by replacing 5’-ggtaccgagctc-3’ in pcDNA3.0 
frame with 5’-gccaccatggactataaggacgatgacgatgacgacaagccgggc-3’. HDAC5 
(NM_005474) cDNA clone was purchased from Origene (Rockville, MD), and then 
flag-HDAC5 was constructed by inserting EcoRV-XbaI fragment amplified from 
PCR into the pcDNA3.0 n-flag. 
Cell Lines and Cell Culture 
Hep3B, HeLa and MCF7 cell lines were obtained from ATCC and cultured according 
to their instructions. Hypoxic treatments were carried out by directly incubating cells 
in O2 station (In VIVO2, Ruskinn Technology Limited, UK).  
RNA Interference 
HDAC1 (s73), HDAC3 (s16687), HDAC4 (s18839), HDAC5 (s19463), HDAC6 
(s19459) and negative control (22400105) siRNA were purchased from Life 
Technologies. Transient transfection was performed with Lipofectamine 2000 
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reagents (Invitrogen, Life Technologies) by following the protocol provided by the 
manufacturer.  
Antibodies and Western Blotting 
Anti-HIF-1α polyclonal antibody (NB100-519) was purchased from Novus (Littleton, 
CO). Anti-HDAC4 (#2072) and anti-HDAC5 (#2082) antibody were purchased from 
Cell Signaling Technology (Danvers, MA). Anti-α-tubulin (081M4861) monoclonal 
antibody was purchased from Sigma-Aldrich. Horseradish peroxidase-coupled 
secondary antibodies were from Sigma–Aldrich and Life Technologies. For regular 
Western Blotting, cells were lysed in urea buffer (8 M urea, 10 mM Tris, 10% 
glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1× 
protease inhibitor mix, pH 6.8) on ice with an Ultra-TurraxT8 homogenizer (IKA 
Works, Wilmington, NC) for 30 s followed by incubation on ice for 10 min. Western 
blotting was performed as previously described (Lao, Chen et al. 2012). Protein 
concentrations were determined by Protein Assay Kit I (Bio-Rad, Hercules, CA). The 
same amount of proteins were loaded into Bio-Rad Mini-protein TGX precast gels or 
self-made 8% SDS-PAGE gels. The proteins were then transferred into Bio-Rad 
PVDF membrane, blocked with 5% non-fat milk in TBST (50 mM Tris, 150 mM 
NaCl, 0.1% Tween 20, pH 7.5), and incubated with desired antibodies. Eventually the 
bands signals were developed by using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific). 
RNA Extraction and qRT-PCR 
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Total RNA was extracted with Qiagen RNeasy kit (Valencia, CA). Complement 
DNA was synthesized by Superscript II Reverse Transcriptase (Invitrogen, Life 
Technologies) with random hexamers as primers. qRT-PCR was performed with 
Taqman gene expression primers and StepOnePlus Real-Time PCR System (Applied 
Biosystems, Life Technologies). The expression level of β-actin was set as 
endogenous control for normalization. Taqman gene expression primers HDAC1 
(Hs02621185_s1), HDAC3 (Hs00187320_m1), HDAC5 (Hs00608366_m1), HDAC6 
(Hs00195869_m1), CA-IX (Hs00154208_m1), GLUT1 (Hs00892681_m1) and β-
actin (Hs99999903_m1) were used in the experiments.  
Statistical Analysis 
For qRT-PCR, Data were first generated and then quantitatively analyzed by StepOne 
software with ΔΔCT method. The relative quantities (RQ) value equals 2-ΔΔCT and the 
± error bars represent the 95% confidence intervals. Since the raw CT values cannot 
correctly represent the variations, I use the converted form 2-CT which is linear and 
more accurately depicts the individual variations to perform the student’s t-test (Livak 
and Schmittgen 2001), p value< 0.01 was considered to be statistically significant.  
Primer List 
N-Flag (HindIII-BamHI) 
5’AGCTTGCCACCATGGACTATAAGGACGATGACGATGACGACAAGCCGG
GC3’ 
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5’GATCCGCCCGGCTTGTCGTCATCGTCATCGTCCTTATAGTCCATGGTGGC
3’ 
HDAC5 (EcoRV-XbaI) 
5’AATGATATCCGCCACCATGAACTCTCCCAACGAGTCG3’ 
5’GATTCTAGACAGGGCAGGCTCCTGCTCCAT3’ 
4. Results 
HDAC5 knockdown reduces HIF-1α protein in Hep3B cells 
The HDACIs showing repressive effect on HIF usually inhibit all Zinc dependent 
Class I and Class II HDACs, which include HDAC1-9 (Chen and Sang 2011). 
HDAC1 is localized to nucleus, forms complexes with HDAC2 and plays important 
role in histone deacetylation and chromatin remodeling; HDAC3 is located in both 
the nucleus and cytosol, and can be recruited by other classes of HDACs; HDAC4 
and 5 are closely related homologues, both shuttling between nucleus and cytosol. 
HDAC5 has diverse interacting partners including transcription factors, co-repressors 
and protein kinases; HDAC6 has been reported to bind misfolded proteins and dynein 
motors, and allow the misfolded protein to be physically transported to molecular 
chaperones Hsp70/Hsp90 and proteasomes for degradation (Chen and Sang 2011). 
Therefore, I initially selected HDAC1 (class Ia), HDAC3 (class Ib), HDAC5 (class 
IIa) and HDAC6 (class IIb) as representatives of each subclass HDAC for a 
nonbiased, siRNA knockdown based screening. 
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To address which HDAC is responsible for HIF-1α stability, I examined the effects of 
individually knockdown of selected representative HDACs on HIF-1α (Figure 2-1). 
The efficiency of each siRNA was previously verified by the manufacturer, to further 
ensure its effect, I collected the siRNA treated cell samples and performed qRT-PCR. 
The qRT-PCR results validated the efficiency of siRNA-based knockdown, showing 
treatment with specific HDAC siRNA could decrease at least 60% of target HDACs 
mRNA levels in Hep3B cells (Figure 2-1A). In addition, the Western blotting results 
also confirmed that specific HDAC siRNA decreased the protein level of target 
HDAC (Figure 2-1B). However, only HDAC5 knockdown remarkably decreased 
HIF-1α protein level (Figure 1B).  These data suggest an individual knockdown of 
HDAC5 is enough to reduce HIF-1α protein level and HDAC5 could be the HDAC 
responsible for HIF-1α stability.   
HDAC5 protects HIF-1α from hydroxylation independent proteasomal 
degradation 
The steady level of HIF-1α protein is majorly determined by a dynamic balance 
between protein de novo synthesis and protein degradation. Even though HIF-1α is 
continuously synthesized in the cytosol, under normoxic condition it will be rapidly 
hydroxylated and eventually degraded. Hypoxia globally impairs hydroxylation and 
accumulates HIF-1α. So interfering either HIF-1α de novo synthesis or degradation 
could affect its protein level.  
Previously our lab showed that TSA and SAHA trigger hydroxylation independent 
proteasomal degradation of HIF-1α (Kong, Lin et al. 2006). If TSA destabilizes HIF-
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1α through inhibiting HDAC5, overexpression of HDAC5 should be able to prevent 
HIF-1α from TSA induced degradation. To test this hypothesis, I treated control cells 
and cells overexpressing increasing amount of flag-HDAC5 with TSA (Figure 2-2A). 
As expected, when amount of HDAC5 was increasing, decreasing of HIF-1α protein 
level induced by TSA was partly prevented (Figure 2-2A). This data proved that TSA 
reduces HIF-1α by inhibiting HDAC5.  
As TSA induces hydroxylation independent proteasomal degradation of HIF-1α 
(Kong, Lin et al. 2006), I next asked whether knockdown of HDAC5 induces HIF-1α 
degradation in the same manner. Firstly I treated Hep3B cells with deferoxamine 
(DFX), a hydroxylation inhibitor, and observed that DFX dramatically increased HIF-
1α protein level (Figure 2-2B, from left to right, compare lane 1 and lane 2). 
However, knockdown of HDAC5 diminished DFX accumulated HIF-1α (Figure 2-
2B, from left to right, compare lane 2 and lane 3). This data suggested that 
knockdown of HDAC5 induced reduction of HIF-1α protein is not dependent on 
hydroxylation, which  recapitulates TSA’s effect on HIF-1α protein. Next I knocked 
down HDAC5 and examined HIF-1α protein levels in the presence of MG132, a 
proteasome inhibitor. I observed that in the presence of MG132, HDAC5 knockdown 
failed to reduce HIF-1α protein level (Figure 2-2C), indicating that knockdown of 
HDAC5 reduced HIF-1α accumulation requires the proteasome activity , in other 
words, knockdown of HDAC5 reduces HIF-1α through proteasome degradation like 
TSA. These data, together with our lab’s previous study (Kong, Lin et al. 2006), 
indicate that knockdown of HDAC5 impairs HIF-1α stabilization and induces HIF-1α 
degradation, not affecting HIF-1α de novo translation. 
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HDAC5 knockdown reduces HIF-1α protein in HeLa and MCF7 cells 
To investigate if the role of HDAC5 in HIF-1α regulation is ubiquitous applicable to 
other cancer cell types, I further performed HDAC knockdown experiments in HeLa 
and MCF7 cells. Again, qRT-PCR results confirmed the efficiency of individual 
siRNA in HeLa and MCF7 cells (Figure 2-3A and Figure 2-4A) and only HDAC5 
knockdown effectively reduced HIF-1α protein levels in both HeLa and MCF7 cells 
(Figure 2-3B and Figure 2-4B). These data support that HDAC5 facilitated HIF-1α 
stabilization is a general mechanism presenting in different cell types.  
HDACIs have been previously reported to destabilize HIF-1α, providing an 
opportunity to inhibit HIF-1 function by targeting HDACs. However, considering the 
complexity of HDACs’ functions, non-selective inhibition of HDACs brings 
unpredictable side effects, such as weight loss, diarrhea, fatigue, electrolyte 
dysfunction, taste disturbances and disordered clotting (Thurn, Thomas et al. 2011). 
Identifying which HDAC specifically controls HIF-1α advances our understanding of 
HDAC regulated HIF-1 function, providing more specific rationales to target HIF-1 
for cancer and cardiovascular disease therapy.  So whether knockdown of HDAC5 
could repress HIF-1 function remains a critical question to be elucidated. In this study, 
I used siRNA to perform an unbiased screening of representative HDACs and 
discovered that knockdown of HDAC5, a Class IIa HDAC, was sufficient to induce 
HIF-1α degradation. As a Class IIa HDAC, HDAC5 locates both in nucleus and 
cytosol,  however, HDAC5 usually performs its transcriptional repression function by 
interacting with other co-repressors and its deacetylase activity is not required (Lahm, 
Paolini et al. 2007). Unlike other HDACs, HDAC5 has relative weak enzymatic 
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activity on common HDAC substrate, the histones with acetyl-lysines (Fischle, 
Dequiedt et al. 2002). In summary, my findings demonstrate that knockdown of 
HDAC5 induces proteasomal degradation of HIF-1α. As HDAC5 have distinctive 
functions in nucleus and cytosol, it is important to find out how HDAC5 regulates 
HIF-1α. 
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Figure 2-1 
 
A                                                                 B 
 
 
 
 
 
 
 
 
 
 
Figure 2-1  HDAC5 knockdown reduces HIF-1α protein in Hep3B cells 
A. Confirming the efficiency of HDAC knockdown. Hep3B cells were treated with 
control, HDAC1, HDAC3, HDAC5 or HDAC6 siRNA. After 42 h, cells were 
harvested, and total RNA samples were collected, reverse transcription PCR was 
performed to generate cDNA, and then qRT-PCR was performed to determine the 
expression levels of relevant genes. siR: siRNA. 
B. HDAC5 knockdown attenuates hypoxia triggered HIF-1α accumulation. Hep3B 
cells were transfected with indicated siRNA. After 42 h, cells were exposed to 
hypoxia (1%O2) for 6 h. Total protein samples were collected and Western Blotting 
was performed to determine the protein levels of HIF-1α, HDAC1, HDAC3, HDAC5 
and HDAC6. The protein levels of α-tubulin were determined and used as loading 
control. 
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Figure 2-2 
 
A                                                                                  B 
 
C 
 
 
 
 
 
Figure2-2 HDAC5 protects HIF-1α from Hydroxylation independent proteasomal 
degradation 
A. HDAC5 overexpression rescues TSA-induced HIF-1α degradation. Hep3B cells 
were transfected with 0.25, 0.5, 2 μg of flag-HDAC5 or control vector, then exposed 
to hypoxia for 6 h. Cells were treated with TSA (300 nM) or DMSO (control) for 6 h. 
HIF-1α and flag were detected by Western Blotting. 
B. HDAC5 knockdown reduces Hydroxylation inhibitor DFX triggered HIF-1α. 
Hep3B were transfected with HDAC5 siRNA or control siRNA, and cells were 
treated with DFX (100 μM) or PBS for 6 h. Western blotting was performed to 
determine the protein levels of HIF-1α in cells tested under each condition. 
 
C. Proteasome inhibitor MG132 restores HIF-1α levels in HDAC5 knockdown cells. 
Hep3B were transfected with HDAC5 siRNA or control siRNA, and cells were 
treated with hypoxia in the presence or absence of MG132 (5 μM) for 6 h. Western 
blotting was performed to determine the protein levels of HIF-1α in cells tested under 
each condition. 
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Figure 2-3 
 
A                                                                        B 
 
 
 
 
 
 
 
 
 
Figure 2-3 HDAC5 knockdown reduces HIF-1α protein in HeLa cells  
A~B. HDAC5 knockdown blocks HIF-1α accumulation in HeLa cells. Experimental 
procedures are the same as in Figure 2-1. The mRNA levels of target genes were 
examined by qRT-PCR, protein samples were collected, and HIF-1α levels 
determined by Western Blotting.  
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Figure 2-4 
 
A                                                                   B 
 
 
 
 
 
 
 
 
 
 
Figure 2-4 HDAC5 knockdown reduces HIF-1α protein in MCF7 cells  
A~B. HDAC5 knockdown blocks HIF-1α accumulation in MCF7 cells. Experimental 
procedures are the same as in Figure 2-1. The mRNA levels of target genes were 
examined by qRT-PCR, protein samples were collected, and HIF-1α levels 
determined by Western Blotting.  
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Chapter 3: HDAC5 is required for HIF-1 function 
1. Abstract 
Hypoxia results in a stressful condition for cells to survive. Insufficient O2 switch the 
cell from aerobic respiration to fermentation, which is less effective, and produces 
lactate instead of CO2. Accumulation of lactate dramatically decreases the pH level 
and interferes biochemistry reactions inside the cells. The less effective energy 
production pathway could not provide enough ATP for cell to grow and proliferate. 
HIF-1 is able to relieve these stresses, such as pH dysregulation, energy insufficiency 
or redox imbalance. HIF-1 stimulates Carbonic anhydrase 9 (CA IX) expressions, 
which export protons to maintain cellular pH level. Glucose transporter 1 (GLUT1) 
level is enhanced by HIF-1, thus increases glucose uptake to promote energy 
production. Lactate dehydrogenase (LDH), which is also a target of HIF-1, 
accelerates lactate formation and NADH consumption to maintain cellular redox 
balance. So HIF-1 is the major regulator of functional cellular adaptation to hypoxic 
stress. I have demonstrated that knockdown of HDAC reduces HIF-1α protein level, 
but the importance of HDAC5 for HIF-1 function remains be validated. Here I 
present data to show knockdown of HDAC5 reduces the accumulation rate of HIF-1α, 
the function determine subunit of HIF-1. My data also indicates that knockdown of 
HDAC5 reduced HIF-1 target genes, CAIX and GLUT1, mRNA levels. The seahorse 
analyzer further validated that knockdown of HDAC5 repress cell glycosylation. 
Taken together, my data indicate knockdown of HDAC5 represses HIF-1 function 
under hypoxic condition. 
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2. Introduction 
HIF-1 is the master transcription factor for cellular adaptation to low O2 availability. 
As O2 is the key element of cellular respiration and energy metabolism, hypoxia leads 
ATP shortage and often keeps cells from differentiation. Thus, HIF-1 enhanced 
glucose metabolism level is essential for cell survival and proliferation under hypoxic 
condition. Carbonic anhydrase 9 (CA IX), glucose transporter 1 (GLUT1) and lactate 
dehydrogenase (LDH) are three well-known metabolic enzymes which are majorly 
regulated by HIF-1 activity and they are widely used as cellular biomarkers for 
hypoxia and HIF-1 function (Semenza 2003). GLUT1 increases glucose uptake to 
enhance energy production; LDH catalyzes pyruvate into lactate and the enhanced 
LDH activity could facilitate the stimulated cellular glycolysis under hypoxic 
condition; CA IX catalyzes the reversible hydration of carbon dioxide, which could 
facilitate the neutralization of exceeded lactate inside the cells (Figure 3-1). Several 
other glycolytic genes are also stimulated by HIF-1, such as hexokinase 2 (HK2), 
phosphofructokinase 2 (PFK2) and pyruvate kinase 2 (Semenza 2003).  As in solid 
tumors the combination of vascular abnormalities and accelerated cell proliferation 
create hypoxic environment inside tumor tissues, HIF-1 function is critical for cancer 
cell survival, proliferation and metasis (Giaccia, Siim et al. 2003, Semenza 2003, 
Welsh and Powis 2003, Brown and Wilson 2004, Powis and Kirkpatrick 2004, 
Schwartz, Bankson et al. 2010). HIF-1 activity is functionally determined by the HIF-
1α subunit as HIF-1α is O2 sensitive but HIF-1β is constitutively expressed inside the 
cells (Loenarz, Coleman et al. 2011). It is well known that  HIF-1α  protein level is 
regulated by an O2 dependent pathway, in which the matured HIF-1α protein is 
49 
 
rapidly hydroxylated under normoxic condition and then recognized by an E3 
ubiquitin-ligase complex containing VHL (Epstein, Gleadle et al. 2001, Ivan, Kondo 
et al. 2001, Jaakkola, Mole et al. 2001, Yu, White et al. 2001) for ubiquitination and 
subsequent degradation (Lando, Gorman et al. 2003, Semenza 2004, Kaelin 2005).  
Since I have already shown that knockdown of HDAC5 destabilizes HIF-1α protein, I 
expect that knockdown of HDAC5 could also repress HIF-1 function. My qRT-PCR 
results showed here indicate that only knock down of HDAC5 is able to reduce the 
mRNA level of both CA IX and GLUT1. I also demonstrate that knockdown of 
HDAC5 inhibits cell glycolysis by using biochemistry method and Seahorse Analyzer.  
3. Materials and methods 
Chemicals and Special Reagents 
Common chemicals and solvents were purchased from either Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Tissue culture and 
transfection reagents were obtained from Life Technologies (Carlsbad, CA).  
Cell lines, Cell Proliferation Assay and Lactate Assays 
Hep3B, HeLa and MCF7 cell lines were obtained from ATCC and cultured according 
to their instructions. Cell culture media DMEM and ingredients were purchased from 
Life Technologies and supplemented with 10% fetal bovine serum. Hypoxic 
treatments were carried out by directly incubating cells in O2 station (In VIVO2, 
Ruskinn Technology Limited, UK). Cell proliferation was determined by using 
CyQUANT®NF-Cell Proliferation Kit (Invitrogen, Life Technologies), eight repeats 
were set up in the experiment and the medium was collected for lactate assay by 
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using L-Lactate Assay Kit from Eton Bioscience Inc. (San Diego, CA). Error bars are 
95% confidence intervals. Student’s t-test was performed and p value < 0.01 was 
considered to be statistically significant. 
RNA Interference 
HDAC1 (s73), HDAC3 (s16687), HDAC4 (s18839), HDAC5 (s19463), HDAC6 
(s19459) and negative control (22400105) siRNA were purchased from Life 
Technologies. Transient transfection was performed with Lipofectamine 2000 
reagents (Invitrogen, Life Technologies) by following the protocol provided by the 
manufacturer. The pGIPZ lentiviral empty shRNA control, shHDAC5-1 
(V2LHS_68644), shHDAC5-2 (V2LHS_68645) and shHDAC5-3 (V2LHS_200875) 
were purchased from Open Biosystems (Thermo Fisher Scientific). Lentivirus was 
produced with Trans-Lentiviral Packaging System (Thermo Fisher Scientific) and 
prepared in HEK293T cells: after transfection with pGIPZ-shRNA, the efficiency was 
determined by the percentage of GFP positive cells and the medium were collected 
and filtered. For lentivirus infection, cells were cultured with lentivirus and 
polyberene for 1 day, then medium was changed to fresh regular cell culture medium. 
Finally the stable knockdown cell populations were selected by appropriate 
concentration of puromycin. 
Antibodies and Western Blotting 
Anti-HIF-1α polyclonal antibody (NB100-519) was purchased from Novus (Littleton, 
CO). Anti-HDAC4 (#2072), anti-HDAC5 (#2082), anti-AMPKα (#2532) and anti-
phospho-AMPKα (Thr 172) (#2535S) monoclonal antibody were purchased from 
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Cell Signaling Technology (Danvers, MA). Anti-flag (050M6000) and anti-α-tubulin 
(081M4861) monoclonal antibody were purchased from Sigma-Aldrich. Horseradish 
peroxidase-coupled secondary antibodies were from Sigma–Aldrich and Life 
Technologies. For regular Western Blotting, cells were lysed in urea buffer (8 M urea, 
10 mM Tris, 10% glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 1× protease inhibitor mix, pH 6.8) on ice with an 
Ultra-TurraxT8 homogenizer (IKA Works, Wilmington, NC) for 30 s followed by 
incubation on ice for 10 min. Western blotting was performed as previously described 
(Lao, Chen et al. 2012). Protein concentrations were determined by Protein Assay Kit 
I (Bio-Rad, Hercules, CA). The same amount of proteins were loaded into Bio-Rad 
Mini-protein TGX precast gels or self-made 8% SDS-PAGE gels. The proteins were 
then transferred into Bio-Rad PVDF membrane, blocked with 5% non-fat milk in 
TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5), and incubated with 
desired antibodies. Eventually the bands signals were developed by using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). 
RNA Extraction and qRT-PCR 
Total RNA was extracted with Qiagen RNeasy kit (Valencia, CA). Complement 
DNA was synthesized by Superscript II Reverse Transcriptase (Invitrogen, Life 
Technologies) with random hexamers as primers. qRT-PCR was performed with 
Taqman gene expression primers and StepOnePlus Real-Time PCR System (Applied 
Biosystems, Life Technologies). The expression level of β-actin was set as 
endogenous control for normalization. Taqman gene expression primers HDAC1 
(Hs02621185_s1), HDAC3 (Hs00187320_m1), HDAC5 (Hs00608366_m1), HDAC6 
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(Hs00195869_m1), CA-IX (Hs00154208_m1), GLUT1 (Hs00892681_m1) and β-
actin (Hs99999903_m1) were used in the experiments.  
Statistical Analysis 
For qRT-PCR, Data were first generated and then quantitatively analyzed by StepOne 
software with ΔΔCT method. The relative quantities (RQ) value equals 2-ΔΔCT and the 
± error bars represent the 95% confidence intervals. Since the raw CT values cannot 
correctly represent the variations, I use the converted form 2-CT which is linear and 
more accurately depicts the individual variations to perform the student’s t-test (Livak 
and Schmittgen 2001), p value< 0.01 was considered to be statistically significant.  
4. Results 
HDAC5 knockdown represses HIF-1α accumulation rate 
HIF-1 is a highly conserved transcription factor, which is a heterodimer composed 
with HIF-1α and HIF-1β. The HIF-1β, also known as aryl hydrocarbon receptor 
nuclear translocator (ARNT), is constitutively expressed and forms dimers with 
different subunits such as aryl hydrocarbon receptor (AhR) and HIF-2α (also known 
as endothelial PAS domain-containing protein 1, EPAS1). As HIF-1α protein stability 
is regulated by multiple mechanisms but HIF-1β protein level is stable, HIF-1 activity 
is majorly determined its α subunit: HIF-1α (Chen and Sang 2011).  
To investigate if HDAC5 is indispensable for the hypoxic activation of HIF-1 
function, I first examined if HDAC5 expression levels affects the rates of nuclear 
accumulation HIF-1α upon hypoxia stimulation. Western blotting showed that 
HDAC5 knockdown slowed down the accumulation of HIF-1α upon hypoxia (Figure 
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3-2), which was partly overcome by addition of MG132, suggesting that HDAC5 
expression level is required for rapid nuclear accumulation of HIF-1α. 
HDAC5 knockdown represses HIF-1 target genes 
Carbonic anhydrase 9 (CA-IX) and glucose transporter 1 (GLUT1) are two well-
known metabolic enzymes which are mainly regulated by HIF-1 transactivation 
activity (Semenza 2003). Previously our lab reported that HDACIs repressed hypoxic 
stimulation of CA-IX and GLUT1. To examine whether HDAC5 knockdown 
represses HIF-1 function, I examined the mRNA levels of CA-IX and GLUT1 in 
control and each HDAC knockdown cells by using qRT-PCR (Figure 3-3). Under 
standard cell culture condition (21% O2), the mRNA levels of CA-IX and GLUT1 are 
low. Notably, 6 h hypoxia overtly increased their expression levels. However, 
HDAC5 knockdown significantly blunted the hypoxia stimulated increase of mRNA 
levels of CA-IX (p=0.0035, Figure 3-3A) and GLUT1 (p=0.0014, Figure 3-3B). 
These data indicate expression of representative HIF-1 target genes are repressed by 
knockdown of HDAC5. 
HDAC5 knockdown represses lactate formation enhanced by hypoxia 
The increase of glycolysis and lactate formation best demonstrates the physiological 
response of HIF-1 activation because the expression of LDH and several other 
glycolytic genes, such as HK2, PFK2 and PK2, are stimulated by HIF-1 (Semenza 
2003). If knockdown of HDAC5 could repress HIF-1 function, it should also repress 
cellular lactate fermentation. To test this hypothesis, I calculate the cellular lactate 
fermentation by measuring LDH activity. Hypoxic treatment stimulated cell 
glycolysis and lactate production (Figure 3-4).  However, in HDAC5 knockdown 
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cells, hypoxia-stimulated lactate production was reduced by approximately 30% 
(Figure 3-4A). This data proved that knockdown of HDAC5 inhibits cellular lactate 
fermentation.   
HDAC5 knockdown represses cell glycolysis 
There are different methods could measure cell glycolysis and lactate fermentation 
level. Other than measuring LDH activity, I also measured the lactate production by 
using Seahorse analyzer, which could represent the real time H+ level in cell culture 
(http://www.seahorsebio.com/products/instruments/analyzers.php). Firstly, I proved 
that HDAC5 shRNA is able to knockdown HDAC5 in cells stably (Figure 3-5A). 
Because the Seahorse metabolic analyzer is not compatible with hypoxia workstation, 
I used DFX, a hydroxylase inhibitor, to stimulate HIF-1 function. Consistently, HIF-
1α protein triggered by DFX was reduced by knockdown of HDAC5 (Figure 3-5B). 
The seahorse analyzer showed that DFX increased lactate production in control cells, 
however, was suppressed in HDAC5 knockdown cells (Figure 3-5C, D).  This data 
further validates that knockdown of HDAC5 repress cell glycolysis and lactate 
fermentation by inhibiting HIF-1 function. Taken together, these data indicate that 
HDAC5 is required for optimal hypoxic activation of HIF-1 target genes. 
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Figure 3-1 
 
 
Figure 3-1 HIF-1 function 
Carbonic anhydrase 9 (CA IX), glucose transporter 1 (GLUT1) and lactate 
dehydrogenase (LDH) are three important metabolic enzymes majorly regulated by 
HIF-1. GLUT1 increases glucose uptake to enhance energy production; LDH 
catalyzes pyruvate into lactate and the enhanced LDH activity could facilitate the 
stimulated cellular glycolysis under hypoxic condition; CA IX catalyzes the 
reversible hydration of carbon dioxide, which could facilitate the neutralization of 
exceeded lactate inside the cells. Several other glycolytic genes are also stimulated by 
HIF-1, such as hexokinase 2 (HK2), phosphofructokinase 2 (PFK2) and pyruvate 
kinase 2. 
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Figure 3-2 
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Figure 3-2 HDAC5 knockdown represses HIF-1α accumulation rate 
A. Time course analysis of HIF-1α accumulation in response to hypoxia. Hep3B cells 
were treated with HDAC5 siRNA or control siRNA. After 44 h, cells were exposed to 
hypoxia (1% O2) from 0 to 4 h, one group was also treated with MG132 (5 μM) from 
0 to 4 h. Western Blotting was performed to determine the protein levels of HIF-1α at 
each time point. These experiments have been repeated multiple times, and results 
were generally consistent. 
B. Quantification of data shown in A. The relative HIF-1α levels were obtained from 
Figure 2A, normalized by α-tubulin, and quantified by Image J.  
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Figure 3-3 
 
A                                                                          B 
 
 
 
 
 
 
 
 
 
Figure 3-3 HDAC5 knockdown represses HIF-1 target genes 
A~B. HDAC5 knockdown represses CA IX and GLUT1. MCF7 cells were first 
treated with control, HDAC1, HDAC3, HDAC5 or HDAC6 siRNA. After 42 h, cells 
were incubated in hypoxia chamber (1% O2) for 6 h; then RNA was collected, reverse 
transcription PCR was first performed to generate cDNA, then qRT-PCR was 
performed to determine mRNA levels of CA IX and GLUT1 as indicator of HIF-1 
function. 
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Figure 3-4 
 
A  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4 HDAC5 knockdown represses lactate formation enhanced by hypoxia 
A. HDAC5 knockdown represses hypoxia-stimulated lactate fermentation. Cells 
transfected with control and HDAC5 siRNA were cultured for 48 h, media were 
collected, and lactate levels were measured, and normalized by cell numbers. 
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Figure 3-5 
 
A                                                               B 
                                                                            
 
 
C                                                              D 
                                                                                                                                               
Figure 3-5 HDAC5 knockdown represses cell glycolysis 
A.  Stable HDAC5 knockdown by shRNA in HeLa cells. Cells lines were constructed 
by using the method listed in Materials and Methods section. The protein level of 
HDAC5 and α-tubulin were determined by Western Blotting. 
B. Stable HDAC5 knockdown by shRNA repress nuclear accumulation of HIF-1α. 
HeLa cells transduced with either control shRNA or HDAC5 shRNA1 were treated 
with DFX for 0~6 h, then nuclear extract were collected. HDAC2 were used as 
nuclear protein normalization. 
C~D. HDAC5 knockdown represses HIF-1-stimulated lactate fermentation. HeLa 
cells (20,000) transduced with either control shRNA or HDAC5 shRNA1 were 
seeded into Seahorse XF24 cell culture microplates. Two groups of cells were treated 
with DFX for 4 h to activate HIF-1 function before examination. (* p<0.05, **p<0.01, 
shR: shRNA).  
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Chapter 4: Cytosolic deacetylase activity of HDAC5 is required for HIF-1α 
stability 
1. Abstract 
HDAC is a huge family and so far 18 human HDACs have been identified. The 
HDACs are classified into four classed based on their homology to yeast HDACs. 
HDAC5 is a Class IIa HDAC, which represents relative low HDAC activity on 
histones. So far only α-tubulin has been reported to be a cytosolic substrate of 
HDAC5 in neuron cells. HDAC5 can be observed both in nucleus and cytosol. Unlike 
other Class I HDACs which deacetylases histones and epigenetically regulates gene 
expression in nucleus, nuclear HDAC5 repress transcription factors’ activity by 
directly interacting with them, and recruits nuclear co-repressors at the same time. 
Moreover, the deacetylase activity of HDAC5 is not required for its nuclear inhibitory 
ability.  Since I have identified that HDAC5 is required for HIF-1α stability and HIF-
1 function, I address two questions here: 1) is the deacetylase activity of HDAC5 
required for HIF-1α stability? 2) does HDAC5 regulates HIF-1α in nucleus or cytosol? 
To answer these two research questions, I first construct cytosolic HDAC5 mutant 
flag-HDAC5 S278/279A, nuclear HDAC5 mutant flag-HDAC5 L1092A, and 
deacetylase defect HDAC5 mutant flag-HDAC5 C698A/H704A. I compared these 
mutants with WT HDAC5 and examine their effects on HIF-1α. My data indicate that 
the enzymatic activity of HDAC5 is indispensable for HIF-1α stability. I further 
demonstrate that cytosolic HDAC5 best facilitates HIF-1α stabilization. As HDAC4 
and HDAC5 are highly homologues, I also present data to show HDAC4 
independently stabilizes HIF-1α in a way similar to HDAC5. Taken together, my data 
61 
 
indicate cytosolic and enzymatically active HDAC5 facilitates HIF-1α protein 
stabilization. 
2. Introduction 
HDAC is a huge family of enzymes which remove acetyl groups from N-ε-lysines 
(Ahringer 2000, Yang and Seto 2003, Yang and Gregoire 2005). Since the substrate 
of HDAC is not limited to histones, now HDAC is also defined as lysine deacetylase 
to more precisely describe its actual substrate acetyl-lysine (Choudhary, Kumar et al. 
2009).  So far 18 human HDACs have been identified, and they are classified into 
four classes based on their homology to yeast (Saccharomyces cerevisiae) HDAC 
(Blander and Guarente 2004, Bali, Pranpat et al. 2005, Marks and Dokmanovic 2005). 
HDAC1, HDAC2, HDAC3 and HDAC8 define the Class I HDACs. Generally, Class 
I HDACs are considered to be the major contributor to epigenetic modification 
(Rascle, Johnston et al. 2003, Joseph, Mudduluru et al. 2004). Class I HDACs were 
also reported to be associated with transcription repressive complexes such as Sin3, 
NuRD, CoRest (HDAC1, 2), or SMRT/NCoR (HDAC3) (Ahringer 2000, Yang and 
Seto 2003, Goodson, Jonas et al. 2005, Yang and Gregoire 2005, Rosenfeld, Lunyak 
et al. 2006). HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 define 
Class II HDACs (Yang and Gregoire 2005). HDAC4 is involved in nuclear 
transcriptional co-repressor complex and is implicated in myocyte differentiation, 
skeletogenesis and neuronal survival (Wang, Bertos et al. 1999, Miska, Langley et al. 
2001, Vega, Matsuda et al. 2004, Chen and Cepko 2009); similar to HDAC4, HDAC5 
also interacts with nuclear receptor co-repressor 1 and 2, which are important in the 
down regulation of DNA expression (Huang, Zhang et al. 2000), and regulates the 
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development and pathophysiology of cardiomyocytes (Lemercier, Verdel et al. 2000, 
Vega, Harrison et al. 2004); as an exclusive member in cytosol, HDAC6 deacetylates 
cytoplasmic non-histone substrates such as Hsp90 (Bali, Pranpat et al. 2005, Kovacs, 
Murphy et al. 2005) and α-tubulin (Hubbert, Guardiola et al. 2002, Matsuyama, 
Shimazu et al. 2002, Haggarty, Koeller et al. 2003, Zhang, Li et al. 2003). HDAC6 is 
known to interact with misfolded proteins and dynein motors and allow misfolded 
proteins to be physically transported to proteasome for degradation (Rodriguez-
Gonzalez, Lin et al. 2008). Both Class I and Class II HDACs are Zinc dependent, 
however,  Class III HDAC includes the NAD+ dependent Sirt1-7 (North, Marshall et 
al. 2003, Inoue, Hiratsuka et al. 2007, Vaquero, Sternglanz et al. 2007). HDAC11 is 
the only member of Class IV HDAC (Gao, Cueto et al. 2002). 
Among these HDACs, Class IIa HDACs have relatively weak enzymatic activity on 
the prototypical HDAC substrates such as histones (Fischle, Dequiedt et al. 2002). 
The evolution event responsible for this enzymatic peculiarity is the mutation of a 
tyrosine to histidine inside the catalytic deacetylase domain, which relaxes the active 
site region (in HDAC4 is Y967H) (Lahm, Paolini et al. 2007). Besides of this c-
terminal deacetylase domain, Class IIa HDACs also contains an n-terminal adapter 
domain which devotes to protein-protein interactions. 
HDAC4 and HDAC5 are highly conserved Class IIa HDACs, both dynamically 
shuttles between nucleus and cytosol (Miska, Karlsson et al. 1999, Sparrow, Miska et 
al. 1999, Wang, Bertos et al. 1999). Compared with other Class I and Class II HDACs, 
HDAC4 and HDAC5 performs its transcriptional repression function by interacting 
with other nuclear partners, and its intrinsic deacetylase activity is not required (Lahm, 
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Paolini et al. 2007). For example, HDAC5 represses MEF-2 or β-catenin function in 
nucleus by a directly interaction with them (Zhao, Yue et al. 2011). Phosphorylated 
by AMPK, CaMKII or PKD, HDAC5 will be exported to cytosol and bind to 14-3-3 
(McKinsey, Zhang et al. 2000). So far it is unclear whether HDAC5 has specific 
function in cytosol. It is only reported that HDAC5 deacetylates α-tubulin in neuron 
cells in cytosol and promotes axon regeneration (Cho and Cavalli 2012) (Figure 4-1). 
Since I have already shown that HDAC5 is required for destabilizing HIF-1α protein, 
I expect to reveal how HDAC5 regulates HIF-1α. My data present here indicate that 
cytosolic, enzymatically active HDAC5 facilitates HIF-1α stabilization. I also 
demonstrate that HDAC4 stabilizes HIF-1α in a similar way to HDAC5. 
3. Materials and Methods 
Chemicals and Special Reagents 
Common chemicals and solvents were purchased from either Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Tissue culture and 
transfection reagents were obtained from Life Technologies (Carlsbad, CA).  
Plasmids and DNA Recombination 
All restriction enzymes and other enzymes needed for PCR and DNA recombination 
were purchased from Life Technologies, Thermo Fisher Scientific or La Roche 
(Indianapolis, IN). Vector pcDNA3.0 was purchased from Life Technologies, and 
pcDNA3.0 n-flag was constructed by replacing 5’-ggtaccgagctc-3’ in pcDNA3.0 
frame with 5’-gccaccatggactataaggacgatgacgatgacgacaagccgggc-3’. HDAC5 
(NM_005474) cDNA clone was purchased from Origene (Rockville, MD), and then 
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flag-HDAC5 was constructed by inserting EcoRV-XbaI fragment amplified from 
PCR into the pcDNA3.0 n-flag. The plasmid flag-HDAC4 (Addgene plasmid 13821) 
was purchased from Addgene (Cambridge, MA) (Fischle, Emiliani et al. 1999). 
HDAC3 fragment was generated from PCR and then inserted into pcDNA3.0 n-flag 
BamHI-EcoRI sites. Cytosol localized HDAC5 mutant flag-HDAC5 S278/279A, 
nucleus localized HDAC5 mutant flag-HDAC5 L1092A, AMPK resistant HDAC5 
mutant flag-HDAC5 S259/498A and cytosol localized HDAC4 mutant flag-HDAC4 
S265/266A were constructed by using QuikChange® II Site-Directed Mutagenesis 
Kit (Agilent Technologies, Santa Clara, CA).  Deacetylase activity abolished HDAC5 
mutant flag-HDAC5 C698A/H704A was constructed by Mutagenex Inc (Piscataway, 
NJ). All constructs were confirmed by sequencing analysis. Mutagenesis primers 
were designed by QuikChange Primer Design online 
(http://www.genomics.agilent.com). 
Cell Lines and Cell Culture 
Hep3B, HeLa and MCF7 cell lines were obtained from ATCC and cultured according 
to their instructions. Cell culture media DMEM and ingredients were purchased from 
Life Technologies and supplemented with 10% fetal bovine serum. Hypoxic 
treatments were carried out by directly incubating cells in O2 station (In VIVO2, 
Ruskinn Technology Limited, UK).  
RNA Interference 
HDAC4 (s18839) and negative control (22400105) siRNA were purchased from Life 
Technologies. Transient transfection was performed with Lipofectamine 2000 
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reagents (Invitrogen, Life Technologies) by following the protocol provided by the 
manufacturer.  
Antibodies, Immunoprecipitation and Western Blotting 
Anti-HIF-1α polyclonal antibody (NB100-519) was purchased from Novus (Littleton, 
CO). Anti-HDAC4 (#2072), anti-HDAC5 (#2082) antibody were purchased from 
Cell Signaling Technology (Danvers, MA). Anti-flag (050M6000) and anti-α-tubulin 
(081M4861) monoclonal antibody were purchased from Sigma-Aldrich. Horseradish 
peroxidase-coupled secondary antibodies were from Sigma–Aldrich and Life 
Technologies. For regular Western Blotting, cells were lysed in urea buffer (8 M urea, 
10 mM Tris, 10% glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 1× protease inhibitor mix, pH 6.8) on ice with an 
Ultra-TurraxT8 homogenizer (IKA Works, Wilmington, NC) for 30 s followed by 
incubation on ice for 10 min. Western blotting was performed as previously described 
(Lao, Chen et al. 2012). Protein concentrations were determined by Protein Assay Kit 
I (Bio-Rad, Hercules, CA). The same amount of proteins were loaded into Bio-Rad 
Mini-protein TGX precast gels or self-made 8% SDS-PAGE gels. The proteins were 
then transferred into Bio-Rad PVDF membrane, blocked with 5% non-fat milk in 
TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5), and incubated with 
desired antibodies. Eventually the bands signals were developed by using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). 
Immunofluorescent Cell Staining 
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Cells were cultured in chamber slides before fixation. After fixation with 4% 
formaldehyde in PBS  for 6 min and permeabilization with 0.2% Triton X-100 in PBS 
for 6 min, the slides were sequentially incubated with anti-flag (1:200) and Alexa 
Fluor® 633 goat anti-mouse IgG (Invitrogen, Life Technologies), and mounted with 
SlowFade® Gold antifade reagent with DAPI (Invitrogen, Life Technologies) to 
counterstain DNA. The slides were examined under Olympus (Center Valley, PA) 
FluoView 1000 Confocal Microscope at Drexel's Cell Imaging Center. 
Primer List 
HDAC3 (BamHI-EcoRI) 
5’CGGGATCCATGGCCAAGACCGTGGCCTATTTC3’  
5’GGAATTCTTAAATCTCCACATCGCTTTCCTTGTCATTG3’ 
HDAC4 S265/266A 
5’AGTGGCCGAAAGACGGGCCGCCCCCCTGTTACGCAGG3’ 
5’CCTGCGTAACAGGGGGGCGGCCCGTCTTTCGGCCACT3’ 
HDAC5 (EcoRV-XbaI) 
5’AATGATATCCGCCACCATGAACTCTCCCAACGAGTCG3’ 
5’GATTCTAGACAGGGCAGGCTCCTGCTCCAT3’ 
HDAC5 L1092A 
5’CGCCATGGCCTTGGCGTCGGTGGGGGCC3’ 
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5’GGCCCCCACCGACGCCAAGGCCATGGCG3’ 
HDAC5 S278/279A  
5’CAGAAGGTGGCTGAGCGGAGAGCCGCTCCCCTCCTGCG3’ 
5’CGCAGGAGGGGAGCGGCTCTCCGCTCAGCCACCTTCTG3’ 
N-Flag (HindIII-BamHI) 
5’AGCTTGCCACCATGGACTATAAGGACGATGACGATGACGACAAGCCGG
GC3’ 
5’GATCCGCCCGGCTTGTCGTCATCGTCATCGTCCTTATAGTCCATGGTGGC
3’ 
4. Results 
Deacetylase activity of HDAC5 is required for HIF-1α stability 
HDAC5 is reported to affect tubulin function by deacetylating α-tubulin (Cho and 
Cavalli 2012), but is also found to repress MEF2 transcription activity without 
deacetylase activity (Lemercier, Verdel et al. 2000), so it is important to determine 
whether the intrinsic HDAC5 deacetylase activity is required for HIF-1α stability. To 
answer this question, I first constructed a flag-HDAC5 mutant whose deacetylase 
activity is deficient. It has been previously reported that HDAC4 C669/H675A 
mutant is completely deficient of deacetylase activity, because the active site of the 
deacetylase domain is disrupt by these two mutated residues and the Zinc molecular 
is not be able to bind to the domain (Bottomley, Lo Surdo et al. 2008). As HDAC4 
and HDAC5 are highly homologous and they have a conserved catalytic domains 
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(Figure 4-2A), mutating the conserved residues, C698 and H704, of HDAC5 to A is 
expected to abolish HDAC5 deacetylase activity. To determine whether the 
enzymatic activity of HDAC5 is required for HIF-1α stability, I co-transfected HIF-
1α with C698/H704A HDAC5 plasmid or WT HDAC5 plasmid and then performed 
Western blotting to examine the effects of HDAC5 on HIF-1α. Western blotting 
revealed that WT HDAC5 increased HIF-1α protein level, but C698/H704A HDAC5 
showed no effect on HIF-1α (Figure 4-2B). These results indicate that HDAC5 
increases HIF-1α stability, and the deacetylase activity of HDAC5 is strictly required. 
Cytosolic HDAC5 is sufficient to stabilize HIF-1α 
HDAC5 is dynamically shuttling between the nucleus and the cytosol because it 
contains both a signal responsive Nuclear Localization Signal (NLS) and a Nuclear 
Export Signal (NES). A reversible phosphorylation on HDAC5 regulates HDAC5 
shuttling between the nucleus and the cytosol (McKinsey, Zhang et al. 2001, Greco, 
Yu et al. 2011). Previous report showed that a mutation of S278/279A impairs 
nuclear localization of HDAC5, and a mutation of L1092A blocks nuclear exporting 
of HDAC5 (McKinsey, Zhang et al. 2001, Greco, Yu et al. 2011). To determine 
whether HDAC5 stabilizes HIF-1α through a nuclear or cytosolic function, I 
generated the S278/279A HDAC5 and the L1092A HDAC5 mutants (Figure 4-3A). 
Firstly, I confirmed the subcellular localization of these mutations by using 
immunofluorescent staining (Figure 4-3B). WT flag-HDAC5 was detected in both 
the nucleus and the cytosol (Figure 4-3B.a); S278/279A HDAC5 was found only in 
cytosol (Figure 4-3B.b); and most of the L1092A HDAC5 was localized in nucleus 
(Figure 4-3B.c). Next, I co-transfected HIF-1α with WT HDAC5 or these HDAC5 
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mutants. The Western blotting data showed that WT HDAC5 is able to increase HIF-
1α protein level. Compared to WT HDAC5, the nuclear localized mutant barely 
affected HIF-1α level, but cytosol localized HDAC5 dramatically increased HIF-1α 
protein level (Figure 4-3C). These data indicate that nuclear HDAC5 is not necessary, 
but the cytosolic HDAC5 is sufficient to enhance HIF-1α stability  
HDAC4 stabilizes HIF-1α similarly to HDAC5 
HDAC4 and HDAC5 are highly conserved Class IIa HDACs (Miska, Karlsson et al. 
1999, Sparrow, Miska et al. 1999, Wang, Bertos et al. 1999). Since my data indicates 
that HDAC5 is required for HIF-1α stability, HDAC4 may have similar effect on 
HIF-1α. To further investigate whether HDAC4 has similar effect on HIF-1α, I 
overexpress HDAC3 (non-Class IIa HDAC as control), HDAC4 and HDAC5 (Class 
IIa HDAC) to examine their effects on HIF-1α. Compared with control, cells 
overexpressing HDAC5 showed increased level of HIF-1α, and overexpression of 
HDAC4 also increased HIF-1α protein level, but less effectively than HDAC5 
(Figure 4-4A). HDAC3 showed no effect on HIF-1α (Figure 4-4A). Because 
HDAC4 is reported to shuttle between the nucleus and the cytosol (Miska, Karlsson 
et al. 1999), I asked if cytosolic HDAC4 could stabilize HIF-1α similarly to HDAC5. 
I generated a cytosolic localized HDAC4 mutant S265/266A and co-transfected it 
with HIF-1α. Compared with WT HDAC4, the cytosolic localized HDAC4 mutant 
S265/266A was found sufficient to stabilize HIF-1α (Figure 4-4B). Previously report 
also showed that nuclear exporting of HDAC5 is accompanied by dimerization with 
HDAC4 (Backs, Backs et al. 2008), so I asked whether the formation of 
HDAC4/HDAC5 dimer is critical for HDAC5 mediated HIF-1α stabilization. 
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Because formation of the dimer depends on the simultaneous expression of both 
HDAC4 and HDAC5, I knocked down HDAC4 by siRNA to examine if the ability of 
HDAC5 on HIF-1α stabilization was affected. When HDAC4 is knockdown, I found 
that overexpression of HDAC5 increased the protein level of HIF-1α, indicating 
HDAC5 mediated stabilization of HIF-1α may not depend on formation of dimer with 
HDAC4 (Figure 4-4C). Taken together, these results indicate that a cytosolic 
deacetylation event catalyzed by HDAC5 (maybe HDAC4 as well) facilitates HIF-1α 
stabilization. 
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Figure 4-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 HDAC5 function and regulation 
HDAC5 shuttles between cytosol and nucleus. Normally HDAC5 performs its 
repressing function in nucleus by directly interacting with target transcription factors, 
such as MEF-2 and β-catenin, and its deacetylase activity is not required. 
Phosphorylated by AMPK, CaMKII or PKD, HDAC5 will be exported to cytosol and 
bind to 14-3-3. So far it is unclear whether HDAC5 has specific function in cytosol. It 
is only reported that HDAC5 deacetylates α-tubulin in neuron cells in cytosol and 
promotes axon regeneration.  
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Figure 4-2 
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Figure 4-2 Deacetylase activity of HDAC5 is required for HIF-1α stability 
A. The schematic structure of HDAC5 and 4. The catalytic domains are highly 
conserved between HDAC4 and HDAC5. HDAC4-C669A/H675A mutant was 
reported to be deacetylase deficient; accordingly, HDAC5-C698A/H704A mutant 
were made, and predicted to be deacetylase deficiency.  
B. Deacetylase activity of HDAC5 is required for HIF-1α accumulation. Hep3B cells 
were transfected with HA-HIF-1α with 2 μg of empty vector, HDAC5-
C698A/H704A or WT-flag-HDAC5. HIF-1α and flag were detected by using 
Western blotting. 
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Figure 4-3 
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Figure 4-3 Cytosolic HDAC5 is sufficient to stabilize HIF-1α 
A. The schematic structures of HDAC5 mutants that are exclusively localized to 
either cytosol or nucleus. Mutation was introduced at NLS (S278/279A for HDAC5 
and S265/266 for HDAC4) or NES (L1092A).  
B. Confirmation of the subcellular localization of HDAC5 mutants. Hep3B cells were 
transfected with 2 μg of flag-HDAC5-WT, HDAC5-L1092A or HDAC5-S278/279A. 
Cells were stained with anti-flag to indicate the subcellular localization of HDAC5 
and DAPI was used to show the nuclei.  
C. HDAC5 localized to cytosol is sufficient to enhance the accumulation of HIF-1α. 
Cells were transfected with 2 μg of HA-HIF-1α. In addition, 2 μg of control vector, 
flag-tagged HDAC5(WT), HDAC5-S278/279A (cytosol), or HDAC5-L1092A 
(nucleus) were cotransfected. HIF-1α and flag-tagged HDAC5 were detected by 
Western Blotting. 
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Figure 4-4 
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Figure 4-4 HDAC4 stabilizes HIF-1α similarly to HDAC5 
A. Specificity of HDAC5-mediated HIF-1α stabilization. Hep3B cells were 
transfected with 2 μg of HA-HIF-1α.  In addition, 2 μg of control vector, flag-tagged 
HDAC3, HDAC4, or HDAC5 were co-transfected. HIF-1α and flag-tagged HDACs 
were detected by Western Blotting.  
B. Similar to HDAC5, cytosolic HDAC4 (S265/266A) is sufficient to stabilize HIF-
1α.  
C. HDAC5 stabilizes HIF-1α independent of HDAC4. HDAC4 siRNA was used to 
knockdown HDAC4. Two μg of HA-HIF-1α were co-transfected with either 2 μg of 
flag-HDAC5, or HDAC5-S278/279A. Anti-flag and anti-HIF-1α were used to 
determine the protein levels of HDAC5 and HA-HIF-1α. 
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Chapter 5: HDAC5 facilitates HIF-1α nuclear accumulation and enhances HIF-1 
function 
 
1. Abstract 
HIF-1α is the functional determine subunit of HIF-1, whose stability is regulated by 
two mechanisms. The first mechanism is O2 sensitive: HIF-1α protein is rapidly 
degraded by proteasome in the presence of adequate O2 through a hydroxylation-
independent ubiquitination process. The second mechanism is O2 independent: the 
folding of newly synthesized HIF-1α to active conformation requires the function of 
molecular chaperones Hsp70/Hsp90; a disrupted molecular chaperones function leads 
HIF-1α to ubiquitination-independent degradation. The newly synthesized nascent 
HIF-1α localized in the cytosol, which has no contribution to the HIF-1 function. 
After the maturation, matured HIF-1α enters nucleus, dimerizes with HIF-1β and 
perform HIF-1 transcription activity. Other factors may affect HIF-1α stability before 
or after HIF-1α maturation. For example, a knockdown of VHL would block the 
ubiquitination of HIF-1α, results in an accumulation of matured HIF-1α; HIF-1α 
transfection would increase newly synthesized HIF-1α in the cytosol. Since I have 
determined that HDAC5 facilitates HIF-1α stabilization in the cytosol, I further asked 
whether HDAC5 regulates the nascent HIF-1α or matured HIF-1α. It is also important 
to know whether HDAC5 could promote HIF-1 function. My data here indicate that 
HDAC5 stabilizes overexpressed nascent HIF-1α in the cytosol, and promotes HIF-
1α to enter the nucleus. What’s more, I confirmed that those nuclear HIF-1α induced 
by HDAC5 was fully functional and was able to stimulate HIF-1 target gene 
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expression. Taken together, HDAC5 promotes HIF-1α maturation in the cytosol and 
enhances HIF-1 transcription activity in the nucleus. 
2. Introduction 
HIF1 is a heterodimer composed of HIF-1α and HIF-1β. As HIF-1β is constitutively 
expressed, HIF-1 is functionally controlled by α subunit-HIF-1α. HIF-1 is a basic 
helix-loop-helix (bHLH) transcription factor which belongs to the PER-ARNT-SIM 
(PAS) subfamily. HIF-1α and HIF-1β are structurally similar and both contain a 
bHLH domain for DNA binding, a PAS domain for hetero-dimerization and 
transactivation domain (TAD) for transcriptional activity regulation (Semenza 2003) 
The general physiological feedback of overexpressing HIF target genes is to promote 
the uptake and utilization of O2 and other nutrients, thus building a new O2 
homeostasis status in the tissue and adjust the tissue adaption to hypoxia (Semenza 
1999, Semenza 2000).  
HIF-1α is regulated on different stages (Figure 5-1) (Lando, Gorman et al. 2003, 
Semenza 2004, Kaelin 2005). There are two well-known O2 sensing regulation 
pathways for HIF-1α. The first mechanism is that HIF-1α protein is rapidly degraded 
by proteasome in the presence of O2 through a hydroxylation-dependent 
ubiquitination process. The prolyl hydroxylase (PHD) hydroxylates HIF-1α at P402 
and P564 in the presence of O2 (Lando, Gorman et al. 2003, Semenza 2004, Kaelin 
2005). Hydroxylated HIF-1α will be recognized by VHL for ubiquitination and 
finally degraded by 26S proteasome (Salceda and Caro 1997, Huang, Gu et al. 1998). 
The second mechanism is that HIF-1α transcriptional activity is regulated by its 
transactivation potential (TAP) which is affected by the interaction with co-activator 
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p300/CBP. Factor inhibiting HIF-1 (FIH), another O2-dependent hydroxylase, 
modifies the N803 in the carboxyl terminal activation domain (HIF-1α C-TAD) and 
interrupt the interaction between HIF-1α and p300/CBP (Lando, Peet et al. 2002, 
Sang, Fang et al. 2002). Lack of O2 reduces the activity of these hydroxylases and 
activates HIF-1 function (Lando, Gorman et al. 2003, Semenza 2004, Kaelin 2005). 
O2 and O2-dependent hydroxylation form the conventional O2 sensing pathway of 
HIF-1 function, illustrating a physiological feedback under hypoxic condition. 
Moreover, HIF-1α protein stability is also regulated by a non O2 sensing pathway. 
The folding of newly synthesized nascent HIF-1α to active conformation requires the 
actions of several molecular chaperones, including Hsp70 and Hsp90. The 
monomeric Hsp70 recognizes short hydrophobic motifs in HIF-1α, which are 
commonly exposed on nascent polypeptide chains. The newly synthesized HIF-1α 
associates with Hsp70 to form an early complex, leading to the delivery of HIF-1α to 
Hsp90 to form the mature complex (Taipale, Jarosz et al. 2010). The Hsp90 
oligomeric double ring structure encloses the entire nascent HIF-1α and ensures the 
correct folding process of HIF-1α.  Evidence showed that Hsp90 inhibitors 17-
allylaminogeldanamycin (17-AAG) is able to induce proteasomal degradation of HIF-
1α in the absence of O2 (Kong, Lin et al. 2006). 
HIF-1 is functionally determined by HIF-1α, however, not by the newly synthesized 
HIF-1α. Previous data showed that overexpressed HIF-1α induced by transfection 
localized in the cytosol, which had no contribution to HIF-1 function (Kallio, 
Okamoto et al. 1998).  On the contrary, blocking the hydroxylation-dependent 
ubiquitination of HIF-1α, such as using hydroxylation inhibitor or loss of VHL, 
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results in an accumulation of matured HIF-1 and enhanced HIF-1 transcriptional 
activity (Jaakkola, Mole et al. 2001, Semenza 2003). Since I have determined that 
HDAC5 could facilitate HIF-1α stabilization in the cytosol, it is important to know if 
HDAC5 could accumulate functional HIF-1α. My data here indicate that HDAC5 
stabilizes overexpressed nascent HIF-1α in the cytosol, and promotes HIF-1α to enter 
the nucleus. My qRT-PCR results further confirmed that HDAC5 accumulates 
functional HIF-1α and promotes HIF-1 function. 
3. Materials and Methods 
Chemicals and Special Reagents 
Common chemicals and solvents were purchased from either Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Tissue culture and 
transfection reagents were obtained from Life Technologies (Carlsbad, CA).  
Plasmids and DNA Recombination 
All restriction enzymes and other enzymes needed for PCR and DNA recombination 
were purchased from Life Technologies, Thermo Fisher Scientific or La Roche 
(Indianapolis, IN). Vector pcDNA3.0 was purchased from Life Technologies, and 
pcDNA3.0 n-flag was constructed by replacing 5’-ggtaccgagctc-3’ in pcDNA3.0 
frame with 5’-gccaccatggactataaggacgatgacgatgacgacaagccgggc-3’. HDAC5 
(NM_005474) cDNA clone was purchased from Origene (Rockville, MD), and then 
flag-HDAC5 was constructed by inserting EcoRV-XbaI fragment amplified from 
PCR into the pcDNA3.0 n-flag.  
Cell Lines and Cell Culture 
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Hep3B cell line was obtained from ATCC and cultured according to their instructions. 
Cell culture media DMEM and ingredients were purchased from Life Technologies 
and supplemented with 10% fetal bovine serum. Hypoxic treatments were carried out 
by directly incubating cells in O2 station (In VIVO2, Ruskinn Technology Limited, 
UK).  
Antibodies, Immunoprecipitation and Western Blotting 
Anti-HIF-1α polyclonal antibody (NB100-519) was purchased from Novus (Littleton, 
CO). Anti-flag (050M6000) and anti-α-tubulin (081M4861) monoclonal antibody 
were purchased from Sigma-Aldrich. Horseradish peroxidase-coupled secondary 
antibodies were from Sigma–Aldrich and Life Technologies. For regular Western 
Blotting, cells were lysed in urea buffer (8 M urea, 10 mM Tris, 10% glycerol, 1% 
SDS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1× protease inhibitor 
mix, pH 6.8) on ice with an Ultra-TurraxT8 homogenizer (IKA Works, Wilmington, 
NC) for 30 s followed by incubation on ice for 10 min. Western blotting was 
performed as previously described (Lao, Chen et al. 2012). Protein concentrations 
were determined by Protein Assay Kit I (Bio-Rad, Hercules, CA). The same amount 
of proteins were loaded into Bio-Rad Mini-protein TGX precast gels or self-made 8% 
SDS-PAGE gels. The proteins were then transferred into Bio-Rad PVDF membrane, 
blocked with 5% non-fat milk in TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween 20, 
pH 7.5), and incubated with desired antibodies. Eventually the bands signals were 
developed by using SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific). 
81 
 
Immunofluorescent Cell Staining 
Cells were cultured in chamber slides before fixation. After fixation with 4% 
formaldehyde in PBS  for 6 min and permeabilization with 0.2% Triton X-100 in PBS 
for 6 min, the slides were sequentially incubated with anti-flag (1:200) and Alexa 
Fluor® 633 goat anti-mouse IgG (Invitrogen, Life Technologies), and mounted with 
SlowFade® Gold antifade reagent with DAPI (Invitrogen, Life Technologies) to 
counterstain DNA. The slides were examined under Olympus (Center Valley, PA) 
FluoView 1000 Confocal Microscope at Drexel's Cell Imaging Center. 
RNA Extraction and qRT-PCR 
Total RNA was extracted with Qiagen RNeasy kit (Valencia, CA). Complement 
DNA was synthesized by Superscript II Reverse Transcriptase (Invitrogen, Life 
Technologies) with random hexamers as primers. qRT-PCR was performed with 
Taqman gene expression primers and StepOnePlus Real-Time PCR System (Applied 
Biosystems, Life Technologies). The expression level of β-actin was set as 
endogenous control for normalization. Taqman gene expression primers HIF-1α 
(Hs00153153_m1), HDAC5 (Hs00608366_m1), CA-IX (Hs00154208_m1), GLUT1 
(Hs00892681_m1) and β-actin (Hs99999903_m1) were used in the experiments.  
Statistical Analysis 
For qRT-PCR, Data were first generated and then quantitatively analyzed by StepOne 
software with ΔΔCT method. The relative quantities (RQ) value equals 2-ΔΔCT and the 
± error bars represent the 95% confidence intervals. Since the raw CT values cannot 
correctly represent the variations, I use the converted form 2-CT which is linear and 
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more accurately depicts the individual variations to perform the student’s t-test (Livak 
and Schmittgen 2001), p value< 0.01 was considered to be statistically significant. 
Primer List 
N-Flag (HindIII-BamHI) 
5’AGCTTGCCACCATGGACTATAAGGACGATGACGATGACGACAAGCCGG
GC3’ 
5’GATCCGCCCGGCTTGTCGTCATCGTCATCGTCCTTATAGTCCATGGTGGC
3’ 
HDAC5 (EcoRV-XbaI) 
5’AATGATATCCGCCACCATGAACTCTCCCAACGAGTCG3’ 
5’GATTCTAGACAGGGCAGGCTCCTGCTCCAT3’ 
4. Results 
HIF-1α HDAC5 stabilizes overexpressed HIF-1α 
HIF-1α undergoes post-translational modifications and folding process prior to 
entering the nucleus (Figure 5-1). Previously, our lab has reported that HDACIs, 
such as TSA, induces HIF-1α degradation by disrupting its folding processes, not de 
novo translation (Kong, Lin et al. 2006). Overexpression of recombinant proteins 
usually overwhelms the endogenous folding machinery, which provides a model to 
study the protein folding process. To better understand how HDAC5 regulates HIF-
1α in the cytosol, I first confirmed that overexpression of HDAC5 increases the 
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protein level of co-transfected HA-HIF-1α (Figure 5-2A). To further investigate if 
HDAC5 facilitates the folding processes of newly synthesized nascent HIF-1α, I 
separate the nuclear and the cytosol extracts from control cells and cells co-
transfected with flag-HDAC5 and HA-HIF-1α (Figure 5-2). As α-tubulin is solely 
localized in the cytosol and HDAC2 is exclusively in the nucleus, I used them to 
indicate and differentiate the cytosol and the nuclear extracts (Figure 5-2B).  
Consistent of previous findings, overexpressed HA-HIF-1α was mainly located in the 
cytosol (Figure 5-2B). However, when HDAC5 was overexpressed, the majority of 
HA-HIF-1α was observed in the nucleus (Figure 5-2B). This novel finding indicates 
that HDAC5 may promote HIF-1α maturation and HIF-1 function. 
HDAC5 promotes nuclear localization of overexpressed HA-HIF-1α 
There are different methods can be applied to investigate the subcellular localization 
of proteins. Compared to the biochemistry method, the outcome of immunoflorescent 
staining can be better visualized. To further substantiate the observation, I performed 
immunofluorescent staining on Hep3B cells co-transfected with HA-HIF-1α and flag-
HDAC5 (Figure 5-3). Under exactly the same experimental conditions, and in the 
same microscopic field, I observed that in the cells lacking overexpressed HDAC5, 
HA-HIF-1α was mostly localized in the cytosol (Figure 5-3.c); whereas in cells with 
co-transfected HDAC5, HA-HIF-1α was predominantly observed in the nucleus 
(Figure 5-3.a).  This data further validated that HDAC5 promotes the nuclear 
accumulation of HIF-1α. 
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HDAC5 potentiates HIF-1 transactivation activity 
Theoretically only matured HIF-1α is able to enter the nucleus and perform HIF-1 
function. Since I found that HDAC5 could promote HIF-1α nuclear localization, I 
wonder if the nuclear HIF-1α induced by HDAC5 could enhance HIF-1 
transcriptional activity. To further confirm that HDAC5 facilitated, nuclear localized 
HIF-1α represents a functional protein, I used qRT-PCR to measure the mRNA levels 
of HIF-1 target genes (Figure 5-4).  Overexpression of HIF-1α alone only increased 
HIF-1α mRNA level which was not affected by HDAC5 co-transfection (Figure 5-
4A, B). Importantly, the mRNA levels of CA-IX and GLUT1 were not affected by 
HIF-1α overexpression alone (Figure 5-4C, D), but were remarkably enhanced by 
HDAC5 co-transfection (Figure 5-4C, D).  Taken together, these data suggest that 
increased HDAC5 levels facilitate the nuclear localization of overexpressed HIF-1α, 
thus promoting functional activation of HIF-1.  
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Figure 5-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Model of HIF-1α production and posttranslational folding processes 
in cytosol 
Nascent HIF-1α undergoes posttranslational processes prior to nuclear localization to 
exert transactivation activity of HIF-1 function. Therefore, cytosolic HIF-1  　
represents the portion undergoing these posttranslational processes, while nuclear 
HIF-1  represents mature, function　 al HIF-1α. 
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Figure 5-2 
 
A                                                                      B 
 
 
 
 
 
 
 
Figure 5-2 HDAC5 stabilizes overexpressed HIF-1α 
A. Hep3B cells were transfected with 2 μg of HA-HIF-1α and 2μg of flag-HDAC5 or 
empty vectors. Protein levels of HIF-1α and flag-HDAC5 were determined by 
Western Blotting.   
B. Hep3B cells were transfected with 2 μg of HA-HIF-1α and 2μg of flag-HDAC5 or 
empty vectors, and cytosolic extract and nuclear extracts were separated and 
examined. HDAC2 was used as nuclear normalization. 
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Figure 5-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3 HDAC5 promotes nuclear localization of overexpressed HA-HIF-1α 
Hep3B cells were transfected with 2 μg of HA-HIF-1α and 2μg of flag-HDAC5. Cells 
were stained with anti-flag, anti-HIF-1α and DAPI. A representative microimage 
showing a cell expressing HIF-1α alone and a cell expressing both HIF-1α and 
HDAC5 in the same field was presented here. 
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Figure 5-4 
 
A                                                                        B 
 
 
 
 
 
 
 
C                                                                         D 
 
 
 
 
 
 
 
 
Figure 5-4 HDAC5 potentiates HIF-1 transactivation activity 
A~D. Hep3B cells were co-transfected with 2 μg of HA-HIF-1α and 2μg of flag-
HDAC5. The levels of related mRNA were determined by qRT-PCR. 
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Chapter 6: HDAC5 stabilizes HIF-1α by deacetylating Hsp70 in cytosol 
1. Abstract 
Class IIa HDAC, includes HDAC4, HDAC5, HDAC7 and HDAC9, is a unique group 
of HDAC because compared to other Class I and Class II HDACs, Class IIa HDAC 
has relative weak enzymatic activity on common HDAC substrates such as histones 
with acetyl-lysine. Previously known substrates of HDAC5 only include α-tubulin, 
and α-tubulin deacetylation is the only cytosolic function of HDAC5 that has been 
reported. Since I have determined that the cytosolic enzymatic activity of HDAC5 is 
required for HIF-1α stability, a cytosolic substrate of HDAC5 must be involved. HIF-
1α has been reported to include several acetylation sites. Hyperacetylation of Hsp70 
has been detected when the cells were treated with HDACIs. It also has been reported 
that acetylation of Hsp90 repress the Hsp70/Hsp90 molecular chaperone function. 
Here I present data to show knockdown of HDAC5 reduced the interaction between 
Hsp90 and HIF-1α, which indicates that the function of Hsp70/Hsp90 molecular 
chaperones was inhibited by knockdown of HDAC5. Furthermore, overexpression of 
HDAC5 was found to decrease the interaction between Hsp90 and HIF-1α and 
increase the function of Hsp70/Hsp90 molecular chaperones. When HDAC5 was 
knocked down, I didn't observe any significant change on the acetylation level of 
HIF-1α and Hsp90, however, I observe a dramatically increase of Hsp70 acetylation. 
Next I confirmed Hsp70 is a cytosolic substrate of HDAC5 both in vivo and in vitro. 
Finally I concluded that deacetylation of Hsp70 induced by HDAC5 enhances the 
function of Hsp70/Hsp90 molecular chaperones and stabilizes HIF-1α. 
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2. Introduction 
HDAC is a large family of enzymes which remove acetyl groups from N-ε-lysines 
(Ahringer 2000, Yang and Seto 2003, Yang and Gregoire 2005). Since the substrate 
of HDAC is not limited to histones, now HDAC is also defined more precisely as 
lysine deacetylase (Choudhary, Kumar et al. 2009).  So far 18 human HDACs have 
been identified, and they are classified into four classes based on their homology to 
yeast (Saccharomyces cerevisiae) HDAC (Blander and Guarente 2004, Bali, Pranpat 
et al. 2005, Marks and Dokmanovic 2005). HDAC1, HDAC2, HDAC3 and HDAC8 
belong to Class I HDAC (Rascle, Johnston et al. 2003, Joseph, Mudduluru et al. 
2004), HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 belong to Class 
II HDAC (Yang and Gregoire 2005), the NAD+ dependent Sirt1-7 belong to Class III 
HDAC (North, Marshall et al. 2003, Inoue, Hiratsuka et al. 2007, Vaquero, 
Sternglanz et al. 2007), and  HDAC11 is the only member of Class IV HDAC (Gao, 
Cueto et al. 2002). 
Among these HDACs, Class IIa HDACs have relatively weak enzymatic activity on 
the prototypical HDAC substrates such as histones (Fischle, Dequiedt et al. 2002). 
The evolution event responsible for this enzymatic peculiarity is the mutation of a 
tyrosine to histidine inside the catalytic deacetylase domain, which relaxes the active 
site region (in HDAC4 is Y967H) (Lahm, Paolini et al. 2007). Besides of this c-
terminal deacetylase domain, Class IIa HDACs also contains an n-terminal adapter 
domain which devotes to protein-protein interactions, which also is a huge difference 
from other HDACs. Previously HDAC5 was thought only to be functional in nucleus. 
HDAC5 represses transcription factors by interacting with them and recruiting other 
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nuclear co-repressors, moreover, its intrinsic deacetylase activity is not required 
(Lahm, Paolini et al. 2007). For example, HDAC5 represses MEF-2 or β-catenin 
function in nucleus by a directly interaction with them (Zhao, Yue et al. 2011). A 
HDAC5 deletion without the deacetylase domain still showed the repressive effect on 
MEF-2 (Lemercier, Verdel et al. 2000). Phosphorylated by AMPK, CaMKII or PKD, 
HDAC5 will be exported to cytosol and bind to 14-3-3, and cytosolic HDAC5 is 
previously thought be in an “inactive” state (McKinsey, Zhang et al. 2000). Recently 
α-tubulin was reported to be a cytosolic substrate of HDAC5 and α-tubulin 
deacetylation is the only cytosolic function of HDAC5 that has been reported. This 
report showed that in injured axon, calcium influx activates PKC and induces 
HDAC5 nuclear exporting, thus enhancing α-tubulin deacetylation and mediating 
axon regeneration (Cho and Cavalli 2012).  Even though α-tubulin is a well-known 
substrate of HDAC6 (Hubbert, Guardiola et al. 2002), the stress-induced HDAC5 
nuclear export to deacetylate tubulin signifies an active role of cytosolic HDAC5 in 
cells response to stresses  (Cho and Cavalli 2012). Other cytosolic substrate of 
HDAC5 may exist, but remains unclear. 
Acetylation of HIF-1α has been reported early, a shorter mouse variant isoform 
mARD1 which is orthologous to yeast N-α-acetylase, catalyzes N-ε-acetylation of 
HIF-1α ODD at L532 and promotes HIF-1α recognition by VHL (Jeong, Bae et al. 
2002). The human hARD1 isoform was also detected to interact with HIF-1α ODD in 
vitro and with full length HIF-1α in vivo (Arnesen, Kong et al. 2005). However, 
subsequent evidence has shown that hARD1 is not able acetylate human HIF-1α 
(Arnesen, Kong et al. 2005, Bilton, Mazure et al. 2005, Fisher, Des Etages et al. 2005, 
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Murray-Rust, Oldham et al. 2006). In addition, siRNA silencing of hARD1 showed 
no effects on HIF-1α stability (Bilton, Mazure et al. 2005, Fisher, Des Etages et al. 
2005). As a result, acetylation of HIF-1α remains controversial. Hsp90 has previously 
identified as a substrate of HDAC6 (Bali, Pranpat et al. 2005, Kovacs, Murphy et al. 
2005). Inhibition of HDAC6 leads to Hsp90 acetylation and disruption of 
Hsp70/Hsp90 molecular chaperones function, resulting in degradation of Hsp90 client 
proteins (Bali, Pranpat et al. 2005). Hsp90 facilitated maturation of glucocorticoid 
receptor is also disrupted by HDAC6 inhibition, resulting glucocorticoid receptor 
inactivation (Kovacs, Murphy et al. 2005). Hsp70 acetylation is also documented 
(Wang, Wang et al. 2007, To, Robey et al. 2011).  A HDACI, romidepsin, acetylates 
Hsp70 and inhibits the Hsp70/Hsp90 chaperones function, thus repress the function of 
an Hsp90 client, AhR (To, Robey et al. 2011). Another HDACI FK228 also induces 
acetylation of Hsp90 and represses Hsp70/Hsp90 molecular chaperones function 
(Wang, Wang et al. 2007).  
I first determined that the Hsp70/Hsp90 molecular chaperones function is disrupted 
by knockdown of HDAC5, or enhanced by overexpression of HDAC5. By using 
immunoprecipitation, I identified acetylation of Hsp70 is induced by knockdown of 
HDAC5. Furthermore, both in vivo and in vitro experiments indicate that Hsp70 is a 
substrate of HDAC5. 
3. Materials and Methods 
Chemicals and Special Reagents 
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Common chemicals and solvents were purchased from either Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Tissue culture and 
transfection reagents were obtained from Life Technologies (Carlsbad, CA).  
Plasmids and DNA Recombination 
All restriction enzymes and other enzymes needed for PCR and DNA recombination 
were purchased from Life Technologies, Thermo Fisher Scientific or La Roche 
(Indianapolis, IN). Vector pcDNA3.0 was purchased from Life Technologies, and 
pcDNA3.0 n-flag was constructed by replacing 5’-ggtaccgagctc-3’ in pcDNA3.0 
frame with 5’-gccaccatggactataaggacgatgacgatgacgacaagccgggc-3’. HDAC5 
(NM_005474) cDNA clone was purchased from Origene (Rockville, MD), and then 
flag-HDAC5 was constructed by inserting EcoRV-XbaI fragment amplified from 
PCR into the pcDNA3.0 n-flag. HDAC3 fragment was generated from PCR and then 
inserted into pcDNA3.0 n-flag BamHI-EcoRI sites. Hsp70 fragment was generated 
from PCR and then inserted into pcDNA3.0 n-flag BamHI-XhoI sites. Deacetylase 
activity abolished HDAC5 mutant flag-HDAC5 C698A/H704A was constructed by 
Mutagenex Inc (Piscataway, NJ). All constructs were confirmed by sequencing 
analysis.  
Cell Lines and Cell Culture 
Hep3B cell line was obtained from ATCC and cultured according to their instructions. 
Cell culture media DMEM and ingredients were purchased from Life Technologies 
and supplemented with 10% fetal bovine serum. Hypoxic treatments were carried out 
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by directly incubating cells in O2 station (In VIVO2, Ruskinn Technology Limited, 
UK).  
RNA Interference 
HDAC5 (s19463) and negative control (22400105) siRNA were purchased from Life 
Technologies. Transient transfection was performed with Lipofectamine 2000 
reagents (Invitrogen, Life Technologies) by following the protocol provided by the 
manufacturer.  
Antibodies, Immunoprecipitation and Western Blotting 
Anti-HIF-1α polyclonal antibody (NB100-519) was purchased from Novus (Littleton, 
CO). Anti-acetyl-lysine (#9441) antibody was purchased from Cell Signaling 
Technology (Danvers, MA) and anti-acetyl-lysine (#12210519) antibody was 
purchased from Stressgen (San Diego, CA). Anti-flag (050M6000) and anti-α-tubulin 
(081M4861) monoclonal antibody were purchased from Sigma-Aldrich. Horseradish 
peroxidase-coupled secondary antibodies were from Sigma–Aldrich and Life 
Technologies. For regular Western Blotting, cells were lysed in urea buffer (8 M urea, 
10 mM Tris, 10% glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 1× protease inhibitor mix, pH 6.8) on ice with an 
Ultra-TurraxT8 homogenizer (IKA Works, Wilmington, NC) for 30 s followed by 
incubation on ice for 10 min. For immunoprecipitation, cells were lysed with IP 
buffer (50 mM Tris–HCl, 150 mM NaCl, 1% Triton-X-100, 5 mM EDTA, 50 mM 
NaF, 0.1 mMNa3VO4, and Protease Inhibitor Cocktail). Proteins were 
immunoprecipitated by using antibody and ImmunoPure® Immobilized Protein G 
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agarose beads (Thermo Fisher Scientific). Western blotting was performed as 
previously described (Lao, Chen et al. 2012). Protein concentrations were determined 
by Protein Assay Kit I (Bio-Rad, Hercules, CA). The same amount of proteins were 
loaded into Bio-Rad Mini-protein TGX precast gels or self-made 8% SDS-PAGE gels. 
The proteins were then transferred into Bio-Rad PVDF membrane, blocked with 5% 
non-fat milk in TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5), and 
incubated with desired antibodies. Eventually the bands signals were developed by 
using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). 
Primer List 
HDAC5 (EcoRV-XbaI) 
5’AATGATATCCGCCACCATGAACTCTCCCAACGAGTCG3’ 
5’GATTCTAGACAGGGCAGGCTCCTGCTCCAT3’  
Hsp70 (BamHI-XhoI) 
5’CGCGGATCCATGGCCAAAGCCGCGGCGATC3’ 
5’CCGCTCGAGCTAATCTACCTCCTCAATGGTGGGGCC3’ 
N-Flag (HindIII-BamHI) 
5’AGCTTGCCACCATGGACTATAAGGACGATGACGATGACGACAAGCCGG
GC3’ 
5’GATCCGCCCGGCTTGTCGTCATCGTCATCGTCCTTATAGTCCATGGTGGC
3’ 
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4. Results 
HDAC5 knockdown represses Hsp90, but promotes Hsp70 interaction with HIF-
1α 
HIF-1α is a client of Hsp70/Hsp90 molecular chaperones (Kong, Lin et al. 2006). Our 
lab previously reported that HDACIs reduces HIF-1α by promoting HIF-1α-Hsp70 
interaction and disrupting HIF-1α-Hsp90 interaction. So I asked if knockdown of 
HDAC5 could also affect HIF-1α interaction with Hsp70 and Hsp90. To examine 
how knockdown of HDAC5 affects the physical interaction between HIF-1α and 
Hsp70, or Hsp90, I precipitated HIF-1α protein and measured co-precipitated Hsp70 
and Hsp90 by using Western blotting (Figure 6-1). Compared with control, 
knockdown of HDAC5 co-precipitated 60% more Hsp70, however, 40% less Hsp90 
(Figure 6-1A). This data indicates that knockdown of HDAC5 induces HIF-1α 
degradation by disrupting the function of Hsp70/Hsp90 molecular chaperones. 
HDAC5 overexpression enhances Hsp90 interaction with HIF-1α 
Since my data showed that knockdown of HDAC5 represses Hsp70/Hsp90 molecular 
chaperones, overexpression of HDAC5 should enhance the function of Hsp70/Hsp90 
molecular chaperones. To test this hypothesis, I co-transfected HIF-1α and HDAC5, 
and then precipitated HIF-1α by using immunoprecipitation. Compared with control, 
overexpression of HDAC5 co-precipitated 30% less Hsp70, but 80% more Hsp90 
(Figure 6-2A). This data further confirmed that HDAC5 enhances the function of 
Hsp70/Hsp90 molecular chaperones, thus facilitates HIF-1α maturation and 
stabilization.  
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HDAC5 knockdown shows no effect on HIF-1α acetylation 
Because I have presented data to show a cytosolic deacetylation event catalyzed by 
HDAC5 is involved in HIF-1α stabilization, and all HIF-1α, Hsp70 and Hsp90 have 
been reported to be acetylated proteins (Jeong, Bae et al. 2002, Kovacs, Murphy et al. 
2005, Yang, Fiskus et al. 2013), I asked whether HDAC5 affects the acetylation 
status of one or more of these proteins. I performed immunoprecipitation to test the 
acetylation levels of HIF-1α, Hsp70 and Hsp90 upon knockdown of HDAC5. 
Knockdown of HDAC5 did not significantly affect the total levels of Hsp70 and 
Hsp90, and the protein level of HIF-1α was balanced by treatment of MG132 (Figure 
6-3A). I did not observe any obvious change of the acetylation level of HIF-1α 
(Figure 6-3A).  To further confirm this result, I measured the acetylation level of 
HIF-1α by a different brand of anti-acetyl-lysine antibody. Again, the acetylation 
level of HIF-1α did not seem to be affected by knockdown of HDAC5 (Figure 6-3B).  
HDAC5 knockdown enhances Hsp70 acetylation 
Since the acetylation of HIF-1α was not affected by knockdown of HDAC5, I next 
examined if the acetylation of Hsp70 and Hsp90 were modified by knockdown of 
HDAC5. The total protein levels of Hsp70 and Hsp90 were not affected by 
knockdown of HDAC5. I used anti-acetyl-lysine to precipitate total acetylated 
proteins and used anti-Hsp70 or anti-Hsp90 separately to measure the acetylation 
level of Hsp70 or Hsp90 (Figure 6-4). No increase of Hsp90 acetylation was detected, 
but a remarkable increase of acetylated Hsp70 by knockdown of HDAC5 was 
observed (Figure 6-4A). This evidence suggests that Hsp70 is a potential cytosolic 
substrate of HDAC5. 
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HDAC5 deacetylates Hsp70 
If Hsp70 is a substrate of HDAC5, overexpression of HDAC5 should be able to 
deacetylate Hsp70. To further confirm Hsp70 is a substrate of HDAC5, I co-
transfected Hsp70 with HDAC5 or HDAC3 as control, immunoprecipitated Hsp70 
and used anti-acetyl-lysine antibody to determine the acetylation level of Hsp70. I 
observed that overexpression of HDAC5, but not HDAC3 reduced acetylated Hsp70 
(Figure 6-5A). Western blotting also revealed that WT HDAC5 significantly reduced 
acetylation levels of endogenous Hsp70 when compared with HDAC5 activity 
defective mutant C698/H704A (Figure 6-5B). To test whether Hsp70 acetylation 
status is directly affected by HDAC5 deacetylase activity or a deacetylase activity 
associated with HDAC5 complex, I purified flag-Hsp70 protein from Hep3B cell 
lysate and used purified recombinant HDAC5 to perform the in vitro deacetylation 
assay. The Western blotting result showed that purified recombinant HDAC5 was 
able to deacetylate flag-Hsp70 protein purified from cells in vitro (Figure 6-5C). 
Taken together, these data demonstrate HDAC5 is able to deacetylate Hsp70 in 
cultured cells and in vitro, suggesting acetylated Hsp70 is likely a bona fide substrate 
of HDAC5.  
Overexpression of Hsp70 reduces HIF-1α accumulation 
To further investigate the role of Hsp70 on HIF-1α stability, I performed a co-
transfection of Hsp70 and HDAC5 to test the effect on HIF-1α (Figure 6-6). Not 
surprisingly, overexpression of Hsp70 decreased HIF-1α levels; however, co-
overexpression of HDAC5, which induces Hsp70 deacetylation, prevented the 
decrease of HIF-1α level induced by Hsp70 (Figure 6-6A).  The fact that 
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deacetylated Hsp70 could enhance molecular chaperon client stability is also 
supported by other reports (Wang, Wang et al. 2007, To, Robey et al. 2011). In 
summary, my data suggest a model in which HDAC5 enhances Hsp90-HIF-1α 
interaction by deacetylating Hsp70, and knockdown of HDAC5 recapitulates the 
effects of TSA and SAHA which our lab have previously reported. 
Deacetylation of Hsp70 at K559/561 enhances the stabilization of HIF-1α  
Recently, Yang group reported that Panobinostat, a general Class I and Class II 
HDACI, induce acetylation of Hsp70 at six different lysine residues: K88, K126, 
K159, K524, K559 and K561, which were identified by mass spectroscopy (Yang, 
Fiskus et al. 2013). Among these Hsp70 acetylation sites, K88, K126, K159 and 
K524 have been verified deacetylated by HDAC6 (Yang, Fiskus et al. 2013), but 
which HDAC is responsible for K559/561 deacetylation remains unclear. To examine 
whether K559/561 were deacetylated by HDAC5, I first developed a non-acetylated 
lysine mimic, K559/561R, by replacing lysine with arginine. Next I compared 
K559/561R Hsp70 with WT Hsp70 and found that the acetylation level of WT Hsp70 
was enhanced by HDAC5 knockdown, while the acetylation level of K559/561R 
Hsp70 remained unchanged (Figure 6-7A). This data supported that HDAC5 
deacetylates Hsp70 at K559/561R. To further explore whether K559/561 acetylation 
affects HIF-1α stabilization, I transfected cells with WT Hsp70 or K559/561R Hsp70 
and incubated the cells under hypoxic condition (Figure 6-7B). Consistent with my 
findings, overexpression of WT Hsp70 reduces HIF-1α accumulation; while 
overexpression of K559/561R Hsp70 showed limited effect  (Figure 6-7B). 
Furthermore, when I immunoprecipitated flag-Hsp70, I found that the interaction 
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between Hsp70 and HIF-1α was reduced by K559/561R mutation. This data indicated 
that deacetylation of Hsp70 at K559/561 reduces the interaction between Hsp70 and 
HIF-1α, hence facilitates HIF-1α stabilization.  
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Figure 6-1 
 
A 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 HDAC5 knockdown represses Hsp90, but promotes Hsp70 
interaction with HIF-1α 
A. Cells were treated as indicated and lysates were immunoprecipitated with anti-
HIF-1α. The same blot was firstly used to detect HIF-1α, and then Hsp90, Hsp70 
sequentially. 
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Figure 6-2 
 
A 
 
Figure 6-2 HDAC5 overexpression enhances Hsp90 interaction with HIF-1α 
A. Hep3B cells were co-transfected with 2 μg of HA-HIF-1α and 2 μg of flag-
HDAC5. Cell lysates were immunoprecipitated with anti-HIF-1α, followed by 
detecting Hsp90 and Hsp70 in HIF-1α immunocomplexes. 
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Figure 6-3 
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Figure 6-3 HDAC5 knockdown shows no effect on HIF-1α acetylation  
 
A~B. The cell lysates were immunoprecipitated with anti-HIF-1α. The same blot was 
firstly used to detect Acetyl-lysine (different brands in A and B, see labeling in 
graphs), and then Hsp90, Hsp70 sequentially.  
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Figure 6-4 
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Figure 6-4 HDAC5 knockdown enhances Hsp70 acetylation 
 
A. Hep3B cells were transfected with HDAC5 siRNA or control siRNA and exposed 
to hypoxia in the presence of MG132 (5 μM) for 6 h. Cell lysates were 
immunoprecipitated with anti-acetyl-lysine antibody. The same blot was used to 
detect Hsp90 and Hsp70 sequentially by Western Blotting. 
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Figure 6-5 
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B                                                                            C 
 
 
 
 
 
Figure 6-5 HDAC5 deacetylates Hsp70 
A. HDAC5 deacetylates Hsp70 in cultured cells. Hep3B cells were co-transfected 
with flag-HDAC5with flag-Hsp70, or Flag-HDAC3 with flag-Hsp70. The blot was 
firstly used for acetyl-lysine detection and then for flag-tagged Hsp70 by Western 
Blotting. 
B. HDAC5 deacetylates Hsp70 in cultured cells. Hep3B cells were transfected with 
WT HDAC5 or C698/H704A HDAC5. Cell lysate were immunoprecipitated with 
anti-Hsp70. The blot was used to detect acetyl-lysine proteins and then Hsp70 by 
Western Blotting. 
C. HDAC5 deacetylates Hsp70 in vitro. Hep3B cells were transfected with flag-
Hsp70. flag-Hsp70 were purified by immunoprecipitation with anti-flag antibody. 
The purified flag-Hsp70 was incubated with or without 60 ng of recombinant GST-
HDAC5 (rHDAC5) at 37 °C for 30 min in deacetylase buffer prior to loading on an 
SDS-PAGE. The blot was used to detect acetyl-lysine signal, and then flag-Hsp70 
and flag-HDAC5.  
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Figure 6-6 
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Figure 6-6 Overexpression of Hsp70 reduces HIF-1α accumulation 
A. Cells (from left to right, 1-4) were transfected with 2 μg of HA-HIF-1α. In 
addition the following plasmids were co-transfected:  (1) 2 μg control vector; (2) 1 μg 
flag-Hsp70, 1 μg control vector; (3) 1 μg flag-HDAC5, 1 μg control vector; and (4) 1 
μg flag-Hsp70 and 1 μg of flag-HDAC5. HIF-1α and flag-tagged proteins were 
detected by Western Blotting. 
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Figure 6-7 
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Figure 6-7 Deacetylation of Hsp70 at K559/561 enhances the stabilization of 
HIF-1α  
A. From left to right, Hep3B cells were transfected with: 1. control siRNA+Hsp70 
WT; 2. HDAC5 siRNA+Hsp70 WT; 3. control siRNA+Hsp70 K559/561R; 4. 
HDAC5 siRNA+Hsp70 K559/561R. Cells were exposed to hypoxia in the presence 
of MG132 (5 μM) for 6 h. Cell lysates were immunoprecipitated with anti-acetyl-
lysine antibody.  
B. Cells were transfected with control vectors or Hsp70 vector as indicated in the 
figure (WT Hsp70 or K559/561R Hsp70). Cells were also incubated under normoxic 
or hypoxic conditions for 6h. Total cell lysates were collected and then 
immunoprecipitated with anti-flag antibody. The interaction between HIF-1α and 
flag-Hsp70 were examined.  
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Chapter 7: HDAC5 regulates physiological O2 homeostasis by stabilizing HIF-1α 
1. Abstract 
Class IIa HDAC, includes HDAC4, HDAC5, HDAC7 and HDAC9, is unique 
compared to other Class I and Class II HDACs, because Class IIa has relative weak 
enzymatic activity on common HDAC substrates such as histones with acetyl-lysine. 
Besides this, Class IIa HDAC is also different compared to other HDACs because 
Class IIa HDAC is dynamically shuttling between the nucleus and the cytosol. The 
shuttling of HDAC5 is reversibly regulated phosphorylation induced by certain 
kinases, such as AMPK, CaMKII or PKD. AMPK, known as AMP-activated protein 
kinase, is an enzyme that plays important roles in cellular energy homeostasis. AMPK 
is directly activated by accumulation of AMP associated with low ATP, in other 
words, shortage of energy. Lack of blood flow does not only result in hypoxia, but 
also cause insufficient supply of glucose, so AMPK activation is often accompanied 
with hypoxia in tumors or ischemic region. AMPK directly phosphorylates HDAC5 
at S259 and S498, and exports HDAC5 to cytosol. Cytosolic HDAC5 is binding with 
14-3-3 and was thought to be “inactive” because its nuclear function of inhibiting 
MEF-2 or β-catenin was inactivated. However, recently α-tubulin was reported to be 
a cytosolic substrate of HDAC5 and nuclear exporting of HDAC5 enhances α-tubulin 
deacetylation and mediating axon regeneration.  Since I have found that HDAC5 
facilitates HIF-1α in the cytosol, the shuttling of HDAC5 induced by AMPK may 
have impact on HIF-1α stability. My data presented here indicate AMPK and hypoxia 
are able to induce cytosolic shuttling of HDAC5. Moreover, cytosolic HDAC5 
induced by AMPK or hypoxia increases the protein level of HIF-1α. My cell 
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proliferation data also demonstrate that HDAC5 is beneficial for cell growth under 
hypoxia or glucose deficient conditions. Taken together, stressful signal induced 
cytosolic HDAC5 facilitates HIF-1α stabilization under hypoxia or glucose deficient 
conditions.  
2. Introduction 
HDAC5 contains a Nuclear Exporting Signal at C-terminal and a Nuclear 
Localization Signal at N-terminal adapter domain, which regulates the dynamic 
shuttling of HDAC5 between the nucleus and the cytosol (Miska, Karlsson et al. 1999, 
Sparrow, Miska et al. 1999, Wang, Bertos et al. 1999). Previously HDAC5 was found 
to perform its transcriptional repression function by interacting with other nuclear 
partners, and its intrinsic deacetylase activity is not required (Lahm, Paolini et al. 
2007). Interestingly, the function of HDAC5 is often induced by certain signals. For 
example, HDAC5 could repress MEF-2 function in nucleus by directly interacting 
with MEF-2, but the inhibitory effect is inactivated by CaMK or AMPK (McKinsey, 
Zhang et al. 2000, Zhao, Yue et al. 2011). MEF2, the myocyte enhancer factor-2, is a 
transcription factor that regulates skeletal muscle differentiation (McKinsey, Zhang et 
al. 2000). Calcium/calmodulin dependent protein kinase (CaMK) signaling promotes 
myogenesis by disrupting MEF2-HDAC5 interaction and stimulating HDAC5 to 
enter the cytosol and interact with 14-3-3 (McKinsey, Zhang et al. 2000). CaMK 
phosphorylates in HDAC5 at S259 and S498, which subsequently serve as binding 
docks for 14-3-3 (McKinsey, Zhang et al. 2000). AMPK also regulates cell 
differentiation by disrupting MEF2-HDAC5 interaction (Zhao, Yue et al. 2011). 
AMPK also phosphorylates HDAC5 at S259 and S498, which promotes HDAC5 
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exporting from the nucleus. The mutation of S259/498A HDAC5 is no more under 
regulation of AMPK (Zhao, Yue et al. 2011). The only function of cytosolic HDAC5 
is to deacetylate α-tubulin in axons (Cho and Cavalli 2012). Interestingly the function 
of cytosolic HDAC5 is also activated by specific signal: in injured axon, calcium 
influx activates PKC, phosphorylates HDAC5 and induces HDAC5 nuclear exporting, 
eventually enhancing α-tubulin deacetylation and mediating axon regeneration (Cho 
and Cavalli 2012).  
AMPK is a highly conserved serine or threonine kinase, and is a master regulator of 
cellular energy homeostasis (Winder and Hardie 1999).  AMPK is allosterically 
activated by AMP associated with ATP shortage, thus maintains the glucose 
homeostasis, such as increases glucose uptake by translocating GLUT4, promotes 
glycolysis by increasing HK2 expression, or increases gluconeogenesis by inhibiting 
the transcription of PEPCK and G6Pase (Lage, Dieguez et al. 2008). AMPK is a 
heterotrimeric enzyme consists of α, β, and γ subunits. The AMPK-γ is the subunit 
that provides AMPK its ability to sensitively detect the cellular AMP level. Binding 
of AMP to AMPK-γ subunit exposes the catalytic domain on AMPK-α, thus activates 
AMPK (Adams, Chen et al. 2004). As solid tumors often outgrows blood supply and 
ischemic disorders lacks sufficient blood flow, low glucose supply is often observed 
together with hypoxia (Chen and Sang 2011). As a result, the activation of AMPK 
may also play an important role in HDAC5 facilitated HIF-1α stabilization. 
In this chapter I applied a most recent novel genome engineer technique to achieve 
specific gene down regulation-CRIPSR/Cas Genome Engineering. CRISPR 
(Clustered Regularly Interspaced Short Palindromic Repeats) is a microbial nuclease 
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system to in defend invading phages and plasmids. CRISPR, combined with 
CRISPR-associated (Cas) genes and non-coding RNA elements, is able to program a 
specific CRISPR-mediated nucleic acid cleavage (Cong, Ran et al. 2013). Here I 
constructed HDAC5 knockout cell line by using CRISPR/Cas technique and show 
AMPK-triggered cytosolic shuttling of HDAC5 stabilizes HIF-1α. My cell 
proliferation data also indicate that the AMPK-triggered cytosolic shuttling of 
HDAC5 promotes cell survival under hypoxia and glucose deficient condition. 
3. Materials and Methods 
Chemicals and Special Reagents 
Common chemicals and solvents were purchased from either Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Tissue culture and 
transfection reagents were obtained from Life Technologies (Carlsbad, CA). TSA 
#P9971e was purchased from BioMol (Plymouth Meeting, PA). AICAR (A9978), 
Leptomycin B (L2913) and Compound C (p5499) were purchased from Sigma-
Aldrich. 
Plasmids and DNA Recombination 
All restriction enzymes and other enzymes needed for PCR and DNA recombination 
were purchased from Life Technologies, Thermo Fisher Scientific or La Roche 
(Indianapolis, IN). Vector pcDNA3.0 was purchased from Life Technologies, and 
pcDNA3.0 n-flag was constructed by replacing 5’-ggtaccgagctc-3’ in pcDNA3.0 
frame with 5’-gccaccatggactataaggacgatgacgatgacgacaagccgggc-3’. HDAC5 
(NM_005474) cDNA clone was purchased from Origene (Rockville, MD), and then 
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flag-HDAC5 was constructed by inserting EcoRV-XbaI fragment amplified from 
PCR into the pcDNA3.0 n-flag. Cytosol localized HDAC5 mutant flag-HDAC5 
S278/279A, nucleus localized HDAC5 mutant flag-HDAC5 L1092A, AMPK 
resistant HDAC5 mutant flag-HDAC5 S259/498A were constructed by using 
QuikChange® II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, 
CA).  All constructs were confirmed by sequencing analysis. Mutagenesis primers 
were designed by QuikChange Primer Design online 
(http://www.genomics.agilent.com). 
CRIPSR/Cas Genome Engineering 
Target gene primer was designed by using online CRISPR design tool 
(http://crispr.mit.edu/), and then integrated into pX330 plasmid by following the 
protocol provided by Zhang lab (http://www.genome-engineering.org/crispr). To 
create a stable gene knockout cell line, cells were first co-transfected with 800ng 
pX300 and 200ng pcDNA3.0 plasmid. Finally the stable gene knockout cell 
populations were selected by appropriate concentration of g418 (for Hep3B cell use 
1mg/ml of g418).  
Cell Lines and Cell Culture 
Hep3B, HeLa and MCF7 cell lines were obtained from ATCC and cultured according 
to their instructions. HeLa/Tet-on expressing flag-HDAC5 cell line was constructed 
by using BDTM Tet-on Gene Expression Systems (Clontech, Mountain View, CA). 
Cell culture media DMEM and ingredients were purchased from Life Technologies 
and supplemented with 10% fetal bovine serum. Hypoxic treatments were carried out 
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by directly incubating cells in O2 station (In VIVO2, Ruskinn Technology Limited, 
UK).  
Antibodies and Western Blotting 
Anti-HIF-1α polyclonal antibody (NB100-519) was purchased from Novus (Littleton, 
CO). Anti-HDAC5 (#2082), anti-AMPKα (#2532) and anti-phospho-AMPKα (Thr 
172) (#2535S) monoclonal antibody were purchased from Cell Signaling Technology 
(Danvers, MA). Anti-flag (050M6000) and anti-α-tubulin (081M4861) monoclonal 
antibody were purchased from Sigma-Aldrich. Horseradish peroxidase-coupled 
secondary antibodies were from Sigma–Aldrich and Life Technologies. For regular 
Western Blotting, cells were lysed in urea buffer (8 M urea, 10 mM Tris, 10% 
glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1× 
protease inhibitor mix, pH 6.8) on ice with an Ultra-TurraxT8 homogenizer (IKA 
Works, Wilmington, NC) for 30 s followed by incubation on ice for 10 min. Western 
blotting was performed as previously described (Lao, Chen et al. 2012). Protein 
concentrations were determined by Protein Assay Kit I (Bio-Rad, Hercules, CA). The 
same amount of proteins were loaded into Bio-Rad Mini-protein TGX precast gels or 
self-made 8% SDS-PAGE gels. The proteins were then transferred into Bio-Rad 
PVDF membrane, blocked with 5% non-fat milk in TBST (50 mM Tris, 150 mM 
NaCl, 0.1% Tween 20, pH 7.5), and incubated with desired antibodies. Eventually the 
bands signals were developed by using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific). 
Immunofluorescent Cell Staining 
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Cells were cultured in chamber slides before fixation. After fixation with 4% 
formaldehyde in PBS  for 6 min and permeabilization with 0.2% Triton X-100 in PBS 
for 6 min, the slides were sequentially incubated with anti-flag (1:200) and Alexa 
Fluor® 633 goat anti-mouse IgG (Invitrogen, Life Technologies), and mounted with 
SlowFade® Gold antifade reagent with DAPI (Invitrogen, Life Technologies) to 
counterstain DNA. The slides were examined under Olympus (Center Valley, PA) 
FluoView 1000 Confocal Microscope at Drexel's Cell Imaging Center. 
Primer List 
HDAC5 (EcoRV-XbaI) 
5’AATGATATCCGCCACCATGAACTCTCCCAACGAGTCG3’ 
5’GATTCTAGACAGGGCAGGCTCCTGCTCCAT3’ 
HDAC5 S259A  
5’CCTCCGCAAAACAGCCGCTGAACCCAACTTGAA3’ 
5’TTCAAGTTGGGTTCAGCGGCTGTTTTGCGGAGG3’ 
HDAC5 S278/279A  
5’CAGAAGGTGGCTGAGCGGAGAGCCGCTCCCCTCCTGCG3’ 
5’CGCAGGAGGGGAGCGGCTCTCCGCTCAGCCACCTTCTG3’ 
HDAC5 S498A 
5’AGCCGCACTCAGGCCTCACCGCTGC3’ 
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5’GCAGCGGTGAGGCCTGAGTGCGGCT3’ 
N-Flag (HindIII-BamHI) 
5’AGCTTGCCACCATGGACTATAAGGACGATGACGATGACGACAAGCCGG
GC3’ 
5’GATCCGCCCGGCTTGTCGTCATCGTCATCGTCCTTATAGTCCATGGTGGC
3’ 
4. Results 
AMPK and hypoxia induce cytosolic shuttling of HDAC5 
AMPK is a kinase that has been well characterized as the master energy sensor, 
which regulates the intracellular glucose metabolism and energy homeostasis (Winder 
and Hardie 1999). It has been well documented that glucose depletion activates 
AMPK (Adams, Chen et al. 2004). Moreover, the activation of AMPK by hypoxia 
has also been reported in some cancer cell lines (Laderoute, Amin et al. 2006, Jibb 
and Richards 2008, Mungai, Waypa et al. 2011). It has been reported that AMPK 
phosphorylates HDAC5 on S259 and S498, thus regulates HDAC5 shuttling to the 
cytosol (McKinsey, Zhang et al. 2001, McGee, van Denderen et al. 2008). To 
examine whether AMPK and hypoxia could induce HDAC5 shuttling,   I treated cells 
under various conditions and used immunofluorescent staining to determine the 
subcellular localization of HDAC5. As shown in Figure 7-1, hypoxia was sufficient 
to enhance endogenous HDAC5 levels in cytosol, and this cytosolic localization was 
blocked by Leptomycin B (LMB), a general protein nuclear exporting inhibitor 
(Figure 7-1b, c). Glucose starvation, the prototypical condition that activates AMPK 
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(Towler and Hardie 2007), and AICAR, a typical AMPK activator (Sullivan, 
Brocklehurst et al. 1994),   also promoted cytosolic translocation of HDAC5 (Figure 
7-1d, e). These data supported that the stressful conditions, including hypoxia and 
glucose deficiency, promote cytosolic localization of HDAC5.   
Blocking HDAC5 into cytosol reduces HIF-1α level 
Considering that cytosolic HDAC5 facilitates HIF-1α stabilization, blocking HDAC5 
into cytosol should destabilize HIF-1α and present a lower protein level of HIF-1α. 
To test the hypothesis that nuclear export of HDAC5 is necessary for AMPK-
facilitated HIF-1α stabilization, I treated the cells with either by Compound C 
(AMPK inhibitor) or LMB (general protein nuclear exporting inhibitor) under 
hypoxia condition and measured the HIF-1α protein level by Western blotting 
analysis. My data showed that blocking of HDAC5 export by either Compound C 
(AMPK inhibitor) or LMB impaired HIF-1α accumulation (Figure 7-2). This finding 
suggests that the nuclear exporting of HDAC5 is required for HIF-1α stabilization. 
AMPK induced HDAC5 shuttling affects HIF-1α stability 
To further confirm that the activation of AMPK induced cytosolic accumulation of 
HDAC5 is a key regulatory mechanism in HIF-1α stabilization, I generated an AMPK 
resistant flag-HDAC5 mutant S259/498A , which cannot be phosphorylated by 
AMPK thus remains in nucleus upon AMPK activation (McKinsey, Zhang et al. 2001, 
McGee, van Denderen et al. 2008), to test its effect on HIF-1α. Under glucose 
deficient condition, WT HDAC5 enhanced the accumulation of HIF-1α, while the 
AMPK resistant mutant HDAC5-S259/498A showed no effect on HIF-1α protein 
level (Figure 7-3A). To further investigate the role of AMPK-HDAC5 axis in 
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regulating HIF-1 function under different physiological conditions, I compared the 
effects of WT HDAC5 and exclusively cytosolic mutant S278/279A HDAC5 on HIF-
1α. Under normal culture condition, the cytosolic HDAC5 mutant S278/279A 
stabilized HIF-1α more effectively than WT HDAC5 (Figure 7-3B). Upon AMPK 
activation induced by either hypoxia or glucose starvation that triggers the exporting 
of WT HDAC5 to the cytosol, WT HDAC5 and S278/279A HDAC5 displayed 
similar effects on HIF-1α stabilization, consistent with the notion that cytosolic 
HDAC5 is important for HIF-1α stabilization. These findings suggest that the 
cytosolic function of HDAC5 on HIF-1α stabilization is enhanced by AMPK or 
hypoxia. 
Cytosolic HDAC5 stimulates cancer cell proliferation under hypoxic or glucose 
deficient conditions 
Since HIF-1 promotes cancer cell survival, proliferation and metastasis and AMPK 
and hypoxia enhances the function of HDAC5 on HIF-1α stabilization, HDAC5 
should be to protect cells under stressful low O2 and low glucose conditions. To test 
this hypothesis, I first established a stable HDAC5 knockdown cell line by using 
CRISPR/Cas technique. The protein level of HDAC5 in HDAC5 knockdown cell 
lines was dramatically lower than control cells (Figure 7-4A). Furthermore, the 
nuclear accumulation of HIF-1α was repressed by HDAC5 knockdown (Figure 7-4B). 
Next, I compared the HDAC5 cell proliferation rate of control cells and HDAC5 
knockdown cells under various conditions, including normal cell culture condition 
(21% O2, 25 mM glucose), low glucose (21% O2, 1 mM glucose), hypoxia (1% O2, 
25 mM glucose), hypoxia combined with low glucose (1% O2, 1 mM glucose).  No 
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significant difference was detected under normal cell culture condition (Figure 7-4C).  
This data indicates HDAC5 may not play an important role for cancer cell growth 
under normal condition. Under hypoxia, low glucose, or hypoxia combined with low 
glucose condition, the control cells showed a significant higher proliferation rate than 
HDAC5 knockout cells (Figure 7-4D, E, F), indicating that HDAC5 is able to protect 
cell proliferation under stressful condition. This finding can be well explained by the 
fact that AMPK and hypoxia enhanced the function of HDAC5 on stabilizing HIF-1α. 
Taken together, these data demonstrate that cytosolic translocation of HDAC5 
facilitates rapid nuclear accumulation of functional HIF-1α, and AMPK activation 
represents a physiological signaling pathway that facilitates HIF-1 activation via 
promoting the cytosolic translocation of HDAC5.  
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Figure 7-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1 AMPK and hypoxia induce cytosolic shuttling of HDAC5 
A. Cells with stable flag-HDAC5 overexpression were established and cultured under 
either 21% with 0.25 mM AICAR or 1% oxygen in the presence of 20 ng/ml of LMB 
for 6 h. In addition, one group of cells were cultured in glucose depleted medium (0 
mM) for 12 h. Cells were stained with anti-flag and DAPI. 
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Figure 7-2 
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Figure 7-2 Blocking HDAC5 into cytosol reduces HIF-1α level  
A. AMPK inhibition impairs hypoxic accumulation of HIF-1α. Hep3B cells were 
stimulated with hypoxia from 0-4 h in the presence or absence of compound C (20 
μM). Western Blotting was performed to determine the dynamic accumulation of 
HIF-1α. 
 
B. Blocking nuclear export reduces hypoxia-triggered HIF-1α accumulation.  Hep3B 
cells were treated with hypoxia for 6 h in the presence or absence of LMB (20 ng/ml) 
for 6 h.  
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Figure 7-3 
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Figure 7-3 AMPK induced HDAC5 shuttling affects HIF-1α stability 
A. AMPK-facilitated HIF-1α stabilization depends on cytosolic localization of 
HDAC5. Hep3B cells were transfected with 2 μg of HA-HIF-1α and 2 μg of wild 
type or AMPK-resistant HDAC5 S259/498A mutant. Cells were then treated with 0 
mM glucose medium for 12 h. 
B. AMPK activation enhances the ability of wild type HDAC5 to stabilize HIF-1α. 
Hep3B cells were transfected with 2 μg of HA-HIF-1α and 2 μg of either wild type 
HDAC5 or S278/279A mutant. Cells were treated with hypoxia (1% O2, 6 h) or 
glucose starvation (0 mM Glucose, 12 h). 
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Figure 7-4 
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Figure 7-4 Cytosolic HDAC5 sitimulates cancer cell proliferation under hypoxic 
or glucose deficient conditions  
A. The stable knockdown of HDAC5 cell lines were constructed by using CRISPR 
technique. Hep3B cells were transfected with 800ng pX330-HDAC5 (or empty 
pX330) and 200ng pcDNA3.0 plasmid. The stable knockout cell populations were 
selected by culturing in medium containing 1mg/ml g418. Western Blotting was 
performed to determine the protein levels of HDAC5. 
B. Stable HDAC5 knockdown by CRISPR repress nuclear accumulation of HIF-1α. 
Hep3B control cells or HDAC5 knockdown #5 cells were incubated under hypoxic 
condition from 0~6 h, then nuclear extract were collected. HDAC2 were used as 
nuclear protein normalization. 
C~F. Cell proliferation assay. The stable knockdown of HDAC5 cells or control cells 
were seeded into five microplates (96 well).  Each condition had six repeats. One 
microplate was measured 4 h after seeding as day 0 data. Two microplates were 
incubated in regular cell culture incubator and the other two were incubated in 
hypoxia chamber (1% O2). Cell numbers in these plates were measured separately at 
48 h (day2) and 96 h (day4) time points by using CyQUANT®NF-Cell Proliferation 
Kit. 
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Chapter 8: Specific HDAC5 inhibitor LMK235 disrupts nuclear accumulation of 
HIF-1α and suppresses hypoxic cell proliferation 
 
1. Abstract 
HDAC is a large family of enzymes which remove acetyl groups from N-ε-lysines. 
Class I HDAC and Class II HDAC are Zinc dependent HDACs, which acquires a 
Zinc ion as the co-factor, Class III HDAC is NAD+ dependent including Sirt1-7 and 
HDAC11 is the only member of Class IV HDAC. The HDACIs applied for cancer 
therapeutics encompass diverse small molecular compounds that inhibit Zinc 
dependent HDAC as competitive inhibitor, so these HDACIs are usually general 
Class I and Class II HDAC inhibitors. Clinical and experimental data show that 
HDACIs repress tumor growth and induce apoptosis. However, the mechanism of 
how HDACI repress cancer growth remains unclear. Epigenetic regulation is possible, 
but reduced HIF function caused by HDACI could be another possible reason. For 
examples, TSA, SAHA, butyrate and FK228 are all found to show repressive effect 
on HIF-1 function. Moreover, our lab previously demonstrated that TSA destabilizes 
HIF-1α by disrupting Hsp70/Hsp90 molecular chaperones function. Since the 
inhibition by HDACI is non-selective, side effect such as weight loss, diarrhea, 
fatigue, electrolyte dysfunction, taste disturbances and disordered clotting have been 
observed in clinical application. I have determined that HDAC5 is the HDAC 
responsible for HIF-1α stability and HIF-1 function, so inhibiting   HDAC5 alone 
would increases the anti-cancer efficiency and reduces the side effects. LMK235 is a 
small molecular inhibitor that has been recently developed showing extremely high 
inhibitory effect on HDAC5. Here I presented data to show LMK235 degrades HIF-
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1α through the same pathway of TSA, but by a dramatically lower dose associated 
with its IC50 on HDAC5. My data suggest the anti-cancer effects of HDACIs on 
hypoxic tumor cells may directly correlate to their inhibitory efficiency on HDAC5.  
2. Introduction 
An enzyme inhibitor is a molecule which is capable to bind to the enzyme and 
decreases its enzymatic activity. Generally the binding of an inhibitor to the enzyme 
stops the substrate from entering the enzyme's active site. The binding of an inhibitor 
binding can be reversible or irreversible. Reversible inhibitors usually bind to the 
enzyme or the enzyme-substrate complex non-covalently. Irreversible inhibitors 
usually react with the key amino acid residues of enzyme and change the enzyme 
structure permanently.  
Most small molecule drugs are enzyme inhibitors, so research and development of 
new enzyme inhibitors is an active field in biochemistry and pharmacology. The 
quality of an enzyme inhibitor is often judged by potency, which is defined by the 
concentration needed to inhibit the enzyme. The most common used quantitative 
measurement for the potency is IC50, indicating how much of the inhibitor is required 
to inhibit a given biological process, such as enzymatic activity, protein binding or 
cell availability, by half.  
HDACI includes diverse small molecular compounds that inhibit Zinc dependent 
deacetylases as competitive inhibitor. In competitive inhibition, as the inhibiter and 
the substrate share a similar structure and they are competing for the same enzymatic 
active site, the inhibitor and the substrate are not able to bind to the enzyme at the 
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same time. For example, the hydroxamic acid, a group of HDACI including TSA and 
SAHA, is  bearing a functional group of RC(O)N(OH)R’, whose structure is similar 
the HDAC substrate: N-ε-acetyl-L-lysine (Table 8-1). 
Generally the HDACIs are non-selective Class I and Class II HDAC inhibitors (Chen 
and Sang 2011). So far 18 human HDACs have been identified, and they are 
classified into four classes based on their homology to yeast (Saccharomyces 
cerevisiae) histone deacetylases (Blander and Guarente 2004, Bali, Pranpat et al. 
2005, Marks and Dokmanovic 2005). HDAC1, HDAC2, HDAC3 and HDAC8 define 
the Class I HDACs; HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 
define the Class II HDACs (Yang and Gregoire 2005). Class I and Class II HDACs 
are both Zinc dependent HDACs. Besides this, NAD+ dependent Sirt1-7 define the 
Class III HDAC (North, Marshall et al. 2003, Inoue, Hiratsuka et al. 2007, Vaquero, 
Sternglanz et al. 2007) and HDAC11 is only one in Class IV HDAC family (Gao, 
Cueto et al. 2002). Because Class I and Class II HDACs shared a similar Zinc 
dependent deacetylase domain, the HDACIs usually non-selectively inhibits all Class 
I and Class II HDACs. However, Class IIa HDAC is an exception because the active 
site of Class IIa HDAC has a difference. The Class IIa HDACs have relatively weak 
enzymatic activity on acetyl-lysines (Fischle, Dequiedt et al. 2002). The evolution 
event responsible for this enzymatic peculiarity is the mutation of a tyrosine to 
histidine inside the catalytic deacetylase domain, which relaxes the active site region 
(in HDAC4 is Y967H) (Lahm, Paolini et al. 2007). As a result, the HDACIs showing 
a high potency on Class I HDAC and Class IIb HDAC usually present a low potency 
on Class IIa HDAC (Table 8-1). 
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Several HDACIs have been applied for clinical research, moreover, Vorinostat 
(SAHA) and FK228 have already been approved by FDA for the treatment of 
cutaneous T cell lymphoma (CTCL) (Mie Lee, Kim et al. 2003, Sasakawa, Naoe et al. 
2003).  However, non-selective inhibition of HDACs may bring side effects, such as 
weight loss, diarrhea, fatigue, electrolyte dysfunction, taste disturbances and 
disordered clotting, which have been observed in clinical application (Thurn, Thomas 
et al. 2011). Since I have demonstrated that HDAC5 is the HDAC that responsible for 
HIF-1 function, I expect that inhibition of HDAC5 would be more effective, and 
bring fewer side effects. LMK235 is a specific inhibitor of HDAC5 has been recently 
discovered (Marek, Hamacher et al. 2013). LMK235 and TSA belong to the same 
hydroxamic acid class, however, LMK235 has a much lower IC50 (4.22 nM) for 
HDAC5 compared to TSA (IC50 520 nM), thus being considered a HDAC5 specific 
inhibitor (Table 8-1). Here I presented data to show LMK235 induces HIF-1α 
degradation in the same manner as TSA, but in a more effective way which is 
correlated with HDAC5 IC50 value.  
3. Materials and Methods 
Chemicals and Special Reagents 
Common chemicals and solvents were purchased from either Thermo Fisher 
Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). Tissue culture and 
transfection reagents were obtained from Life Technologies (Carlsbad, CA). 
LMK235 was purchased from Tocris (Bristol, United Kingdom). 
Cell Lines and Cell Culture 
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Hep3B cell line was obtained from ATCC and cultured according to their instructions. 
Cell culture media DMEM and ingredients were purchased from Life Technologies 
and supplemented with 10% fetal bovine serum. Hypoxic treatments were carried out 
by directly incubating cells in O2 station (In VIVO2, Ruskinn Technology Limited, 
UK).  
Antibodies, Immunoprecipitation and Western Blotting 
Anti-HIF-1α polyclonal antibody (NB100-519) was purchased from Novus (Littleton, 
CO). Anti-α-tubulin (081M4861) monoclonal antibody was purchased from Sigma-
Aldrich. Horseradish peroxidase-coupled secondary antibodies were from Sigma–
Aldrich and Life Technologies. For regular Western Blotting, cells were lysed in urea 
buffer (8 M urea, 10 mM Tris, 10% glycerol, 1% SDS, 5 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, 1× protease inhibitor mix, pH 6.8) on ice with an 
Ultra-TurraxT8 homogenizer (IKA Works, Wilmington, NC) for 30 s followed by 
incubation on ice for 10 min. Western blotting was performed as previously described 
(Lao, Chen et al. 2012). Protein concentrations were determined by Protein Assay Kit 
I (Bio-Rad, Hercules, CA). The same amount of proteins were loaded into Bio-Rad 
Mini-protein TGX precast gels or self-made 8% SDS-PAGE gels. The proteins were 
then transferred into Bio-Rad PVDF membrane, blocked with 5% non-fat milk in 
TBST (50 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5), and incubated with 
desired antibodies. Eventually the bands signals were developed by using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). 
Immunofluorescent Cell Staining 
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Cells were cultured in chamber slides before fixation. After fixation with 4% 
formaldehyde in PBS  for 6 min and permeabilization with 0.2% Triton X-100 in PBS 
for 6 min, the slides were sequentially incubated with anti-flag (1:200) and Alexa 
Fluor® 633 goat anti-mouse IgG (Invitrogen, Life Technologies), and mounted with 
SlowFade® Gold antifade reagent with DAPI (Invitrogen, Life Technologies) to 
counterstain DNA. The slides were examined under Olympus (Center Valley, PA) 
FluoView 1000 Confocal Microscope at Drexel's Cell Imaging Center.  
Statistical Analysis 
For cell proliferation IC50 assay, the data was analyzed by Origin 8.0 software and 
fitted by sigmoidal model, the ± error bars represent the 95% confidence intervals. 
4. Results 
HDAC5 specific inhibitor LMK235 reduces HIF-1α level 
A small molecule, HDAC5 specific inhibitor LMK235 has been recently discovered 
(Marek, Hamacher et al. 2013). LMK235 and TSA shared the same hydroxamic acid 
basic structure, however, LMK235 has a much lower IC50 (4.22 nM) for HDAC5 
compared to TSA (IC50 520 nM), thus being considered a HDAC5 specific inhibitor 
(Table 8-1). To investigate whether specifically inhibiting HDAC5 is sufficient to 
suppress HIF-1 function, I treated Hep3B cells with increasing concentrations of 
LMK235 (Figure 8-1).  Western blotting data showed 25 nM was sufficient to 
remarkably reduce HIF-1α levels (Figure 8-1A).  Moreover, in the presence of 
LMK235, accumulation of HIF-1α as a response to hypoxia was impaired (Figure 8-
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1B). These data indicate that the specific HDAC5 inhibitor LMK235 is capable to 
reduce HIF-1α. 
LMK235 induces hydroxylation-independent proteasomal degradation of HIF-
1α 
To determine whether LMK235 induces HIF-1α degradation, I treated cells with 
LMK235 in the presence of MG132, and found that MG132 blocked LMK235-
induced reduction of HIF-1α (Figure 8-2A), recapitulating the effect of TSA and 
SAHA. Consistent with previous data, LMK235 was able to reduce DFX 
accumulated HIF-1α (Figure 8-2B), suggesting LMK235-mediated HIF-1α 
degradation is hydroxylation independent.  
LMK235 blocks HIF-1α nuclear localization 
Nuclear importing of HIF-1α is an essential step to activate HIF-1 function. To test if 
LMK235 could repress HIF-1 function by suppress HIF-1α nuclear accumulation, I 
induced HIF-1α accumulation by hypoxia or DFX, and then treated the cells with 
LMK235. The subcellular localization of HIF-1α was determined by 
immunofluorescent staining. The data showed that hypoxia or DFX could induce 
HIF-1α accumulation tin the nucleus (Figure 8-3.a, c). Moreover, LMK235 blocked 
the nuclear accumulation of both hypoxia and DFX-stimulated HIF-1α (Figure 8-3.b, 
d). These data further suggested that HDAC5 regulates HIF-1α stabilization upstream 
of the hydroxylation-triggered degradation process.  
131 
 
HDAC5 inhibition correlates to the inhibitory effects of HDACs on cancer cell 
proliferation under hypoxia 
If HDACIs repress hypoxic cancer cell proliferation mainly by inhibiting HDAC5, 
the efficacy of the HDAC5 specific inhibitor should be at least as good as the 
HDACIs reported previously. To test this hypothesis, I compared the IC50 of TSA and 
LMK235 on Hep3B cell proliferation for 3 days under hypoxic conditions and 
analyzed the correlation between their IC50 for cell proliferation and their IC50 for 
HDAC enzymatic activities (Figure 8-4A, B). TSA, which has a high IC50 (520 nM) 
for HDAC5 and a low IC50 for HDAC1 (0.4 nM), HDAC3 (1.0 nM) and HDAC6 (2.0 
nM) (Shi, Scott et al. 2011) (Table 8-1), showed an IC50 of 87 nM for cell 
proliferation (Figure 8-4B). On the other hand, LMK235, with a low IC50 for 
HDAC5 (4.22 nM) and very high IC50 for HDAC1 (320 nM) or HDAC6 IC50 (56 nM) 
(Table 8-1), gave an IC50 of 0.4 nM for cancer cell proliferation under hypoxia 
(Figure 8-4A). These data suggest that the anti-proliferation effects of HDACIs on 
hypoxic tumor cells may directly correlate to their inhibitory efficiency on HDAC5.  
HDAC5 inhibition reduces HIF-1α in cardiacmyocytes 
HDAC5 may also regulate HIF-1α in other tissues such as cardiac muscles. Previous 
report showed that HDAC5 knockout mice developed cardiac hypertrophy, which 
may result from a failure of physiological and developmental adaptation to cardiac 
hypoxia (Chang, McKinsey et al. 2004). Other reports showed that an overexpression 
of HIF-1α was sufficient to attenuate the cardiac hypertrophy caused by HDAC5 
knockout (Xue, Cai et al. 2010). To test if HDAC5 could regulate HIF-1α in cardiac 
muscles, I applied multiple methods to reduce or inhibit HDAC5 in H9c2 cells, rat 
132 
 
cardiacmyocytes, and examined their effects on HIF-1α.  Knockdown of HDAC5 
reduces hypoxia triggered HIF-1α accumulation in H9c2 cells (Figure 8-5A). 
Furthermore, 500 nM TSA and 25 nM LMK235 are sufficient to reduce HIF-1α 
protein under hypoxic condition in H9c2 cells (Figure 8-5B, C). These data suggest 
that HDAC5 is also required for HIF-1α stability in normal tissues such as cardiac 
muscles. 
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Table 8-1  IC50 value (nM) of HDACi towards representitive HDACs 
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Figure 8-1 
 
A 
 
 
 
 
B 
 
 
 
 
 
 
Figure 8-1 HDAC5 specific inhibitor LMK235 reduces HIF-1α level 
A. Concentration effects of LMK235 on HIF-1α accumulation. Hep3B cells were 
treated with 0, 25 or 50 nM of LMK235, and exposed to hypoxia for 6 h prior to 
harvest and analysis for HIF-1α levels.   
B. Effects of LMK235 on hypoxia-induced accumulation of HIF-1α. Hep3B cells 
were treated with either DMSO as control or 50 nM of LMK235, and exposed to 
hypoxia from 0 to 6 h. 
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Figure 8-2 
 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
Figure 8-2 LMK235 induces hydroxylation-independent proteasomal 
degradation of HIF-1α 
A. Proteasome inhibitor blocks LMK235-triggered reduction of HIF-1α levels. 
Hep3B cells were treated with hypoxia for 6 h in the presence of 25 nM of LMK235 
or DMSO.  
B. LMK235-induced degradation of HIF-1α is hydroxylation-independent. Hep3B 
cells were treated with DFX (100 μM)) from 0 to 4 h in the presence or absence of 
LMK235 (25 nM).  
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Figure 8-3 
 
 
 
Figure 8-3 LMK235 blocks HIF-1α nuclear localization 
Hep3B cells were treated with 6 h of hypoxia or DFX (100 μM) in the presence or 
absence of 25 nM of LMK235.  Cells were stained with anti-HIF-1α to detect 
endogenous HIF-1α, and DAPI to show nuclei.  
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Figure 8-4 
 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
Figure 8-4 HDAC5 inhibition correlates to the inhibitory effects of HDACs on 
cancer cell proliferation under hypoxia 
A~B. Hep3B cells were split into 96 well microplate and treated with various 
concentrations of TSA or LMK235 for 3 days.  Cells numbers of non-treated samples 
at each time point were countered and set as control (1.0 or 100%). 
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Figure 8-5 
 
A                                                                  B 
 
 
 
 
 
C 
 
 
 
 
 
Figure 8-5 HDAC5 inhibition reduces HIF-1α in cardiacmyocytes 
A. HDAC5 knockdown reduces hypoxia triggered HIF-1α accumulation in H9c2 cells. 
H9c2, a rat cardiacmyocyte cell line, were transfected with HDAC5 siRNA. After 42 
h, cells were exposed to hypoxia (1%O2) for 6 h. Total protein samples were 
collected and Western Blotting was performed to determine the protein levels of HIF-
1α.  
B. TSA reduces hypoxia triggered HIF-1α accumulation in H9c2 cells. H9c2 cells 
were treated with hypoxia, combined with indicated concentration of TSA for 6h. 
Total protein samples were collected and Western Blotting was performed to 
determine the protein levels of HIF-1α. 
C. LMK235 reduces hypoxia triggered HIF-1α accumulation. H9c2 cells were treated 
with hypoxia, combined with indicated concentration of LMK235 for 6h. Total 
protein samples were collected and Western Blotting was performed to determine the 
protein levels of HIF-1α.   
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Chapter 9: Discussion 
HIF-1 is the master regulator of adaptive responses to changes in oxygenation. The 
direct consequence of hypoxia is insufficient energy production because of the 
suppression of oxidation metabolism. So far more than 1,000 HIF-1 targets have been 
identified by gene expression array and chromatin immunoprecipitation (ChIP) 
(Manalo, Rowan et al. 2005, Xia, Lemieux et al. 2009, Schodel, Oikonomopoulos et 
al. 2011). One group of these genes, including HK1, HK2, GLUT1, GAPDH, PFK2 
and etc., are involved in glucose metabolism. The translational application of HIF-1 
varies under different physiological or pathological conditions. For example, HIF-1 
inhibitors could be used for cancer therapy; HIF-1 activators could be utilized for 
ischemic disorders or spinal cord injuries. A better understanding of the regulation of 
HIF-1 under varieties of physiological or pathological conditions could facilitate 
designing better strategies to manipulate HIF-1 to improve outcomes of diseases 
where HIF-1 activation plays a critical role.  
Based on the fact that non-specific HDACIs destabilized HIF-1α, I used siRNA to 
perform an unbiased screening of representative members of HDACs and found 
knockdown of HDAC5, a Class IIa HDAC, was sufficient to induce HIF-1α 
degradation and suppress HIF-1 activation upon hypoxia. HDAC5 is a downstream 
target of AMPK, the master energy sensor, and has transcriptional repressive function 
in nucleus. Usually HDAC5 performs its transcriptional repression function by 
interacting with other partner proteins and its intrinsic deacetylase activity is not 
required (Lahm, Paolini et al. 2007). Considering that HDAC5 are highly expressed 
in heart, neuron, muscle, lung, and placenta, which represent the tissues that are most 
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sensitive to physiological fluctuation of O2 levels and metabolic stresses (Chang, 
McKinsey et al. 2004),  these findings directly link the energy sensor AMPK to HIF-1 
activation.   
My data indicate that a cytosolic HDAC5 activity facilitates HIF-1α stabilization and 
its rapid nuclear accumulation in response to cell stresses. These data are consistent 
with previous findings that HDAC inhibitors trigger hydroxylation-independent, 
ubiquitination-independent, proteasomal degradation of HIF-1α (Kong, Lin et al. 
2006). As a transcription factor, HIF-1α is generally considered a nuclear protein, and 
its stability is physiologically regulated by O2 concentration, which involves a 
hysproxylation-ubiquitination and proteasomal degradation cascade of events. 
However, like most other proteins, de novo HIF-1α is translated and undergoes 
posttranslational processes in cytosol prior to forming its functional native 
configuration. My study provides evidence to support a role of HDAC5 activity in the 
regulation of posttranslational processing of HIF-1. Lack of HDAC5 might cause 
Hsp70 maintain its hyperacetylation status, thus may block HIF-1α folding and 
maturation, leading to increased portion of misfolded HIF-1α in cytosol, which may 
not enter nucleus and has no transactivation activities. This model is also consistent 
with the fact that exogenously overexpressed HIF-1α is not very potent in 
transactivation activity, an observation which is well-known in the HIF biology field.  
As a Class IIa HDAC, HDAC5 is unique because compared to other Class I and Class 
II HDACs, Class IIa HDACs have relative weak enzymatic activity on common 
HDAC substrates such as histones with acetyl-lysine (Fischle, Dequiedt et al. 2002).   
Previously known substrates of HDAC5 only include α-tubulin, and α-tubulin 
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deacetylation is the only cytosolic function of HDAC5 that has been reported. 
Recently, it has been found that in injured axon, calcium influx activates PKC and 
induces HDAC5 nuclear exporting, thus enhancing α-tubulin deacetylation and 
mediating axon regeneration (Cho and Cavalli 2012).  Even though α-tubulin is a 
well-known substrate of HDAC6 (Hubbert, Guardiola et al. 2002), a stress-induced 
HDAC5 nuclear export to deacetylate tubulin signifies an active role of cytosolic 
HDAC5 in cells response to stresses  (Cho and Cavalli 2012). The AMPK-promoted 
nuclear export of HDAC5 has been reported as well, which was considered a passive 
sequestration process to suppress the nuclear function of HDAC5 (McGee, Sparling 
et al. 2006, Zhao, Yue et al. 2011). In this thesis, my data show Hsp70 is another 
cytosolic substrate of HDAC5, and its deacetylation is enhanced by metabolic stresses 
(hypoxia or low glucose) that induce HDAC5 nuclear exporting. It remains unclear 
whether HDAC5 has other cytosolic substrates in addition to α-tubulin and Hsp70, 
nevertheless, my findings suggest that AMPK-promoted HDAC5 nuclear export may 
represent an important cellular response to metabolic stresses such as energy shortage.  
Hypoxia-triggered activation of HIF-1 has been well-known, and the activation of 
AMPK by hypoxia has been reported (Laderoute, Amin et al. 2006, Jibb and Richards 
2008, Mungai, Waypa et al. 2011). However, it remained unclear whether AMPK 
plays a role in the activation of HIF-1. One report showed that AMPK activates HIF-
1 in prostate cancer cells (Lee, Hwang et al. 2003) , whereas AMPK is also thought to 
repress HIF-1 through mTOR signaling inhibition (Shackelford and Shaw 2009).  My 
findings directly link AMPK-induced HDAC5 nuclear exporting to HIF-1α 
stabilization, establishing a direct signaling pathway from cellular energy stress to 
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HIF-1 activation. While hypoxia remains the most important factor that controls the 
levels of mature, functional HIF-1α in cells, AMPK activation caused by hypoxia or 
glucose starvation may facilitate the rapid nuclear accumulation of HIF-1α. This layer 
of regulation may not be critical under normal physiological conditions where cells 
do not need high level of HIF-1 function; it may become critical when cells undergo 
various stresses which demand increased energy production.  
HDAC4 and HDAC5 are homologous Class IIa HDACs, but they are unlikely to be 
functionally redundant. Their tissue-specific expression levels in different tissues vary 
dramatically: HDAC4 is highly expressed in myeloid, whereas HDAC5 are highly 
expressed in heart, neuron, muscle, lung, and placenta, which represent the tissues 
most sensitive to physiological fluctuation of O2 levels and metabolic stresses (Chang, 
McKinsey et al. 2004).  
A role of HDAC4 in HIF-1α stabilization has been reported by another group, and 
mechanistically, it was proposed that HDAC4 directly interacts with and deacetylates 
HIF-1α N-terminal lysines (Geng, Harvey et al. 2011). However, the acetylation of 
HIF-1α has not been confirmed by mass spectrometry in this report. I have used anti-
acetyl lysine antibodies from different sources, but failed to observe any obvious 
change of HIF-1α acetylation levels by HDAC5 knockdown or HDAC inhibitors used 
in my studies. In addition, I did not find any evidence to support a direct physical 
interaction between HDAC4/5 and HIF-1α. Based on my data, HDAC5 (and may be 
HDAC4 as well) stabilizes HIF-1α by deacetylating Hsp70, which is involved in the 
posttranslational maturation and the folding process of HIF-1α. Other evidence to 
support my model include: 1). Hsp70 acetylation is enhanced by HDACIs (Wang, 
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Wang et al. 2007, To, Robey et al. 2011); 2). Hsp70 acetylation at multiple lysyl 
residues has been confirmed by mass spectrometry (Yang, Fiskus et al. 2013); and 3). 
A physical interaction between HDAC5 and Hsp70 has been also shown by multiple 
groups independently (McGee and Hargreaves 2010) and confirmed in this study.   
Taken together, findings in this thesis demonstrate that the HDAC5-induced 
deacetylation of Hsp70 in the cytosol is required for the rapid nuclear accumulation 
of HIF-1α, thus indicating AMPK-stimulated cytosolic shuttling of HDAC5 plays an 
important role in cells’ rapid response to hypoxia and glucose deficiency. 
My findings may provide a potential strategy to repress tumor growth by selective 
HDAC5 inhibition. HDACIs have been found to destabilize HIF-1α and repress HIF-
1 function, providing an opportunity to suppress tumor growth by targeting HDACs. 
However, considering the variety of HDAC family members and the complexity of 
their functions, non-selective inhibition of HDACs may bring unpredictable side 
effects. In fact,  several side effects of HDACIs including weight loss, diarrhea, 
fatigue, electrolyte dysfunction, taste disturbances and disordered clotting have been 
observed in clinical application (Thurn, Thomas et al. 2011). Identifying that HDAC5 
specifically regulates HIF-1α advances our understanding of HDACI-triggered 
suppression of HIF-1, and provides a more specific approach to inhibit HIF-1 
activation.  
In addition, overexpression of HDAC5 was found associated with several kinds of 
solid tumors (Wang, Zou et al. 2009, Milde, Oehme et al. 2010). High level 
expression of HDAC5 has been detected in most of medulloblastomas, the most 
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common malignant brain tumor, which is an independently parameter increasing 
patients’ mortality, and HDAC5 knockdown reduced medulloblastoma cell growth 
and viability (Milde, Oehme et al. 2010). HDAC5 expression has also been found to 
be increased in prostate cancer specimens and in prostatic intraepithelial neoplasia, 
whereas the change of HDAC4 expression is insignificant (Wang, Zou et al. 2009).  
Previously our lab reported that SAHA and TSA trigger proteasome-dependent 
degradation of HIF-1α, which requires relatively high concentrations to show the 
repressive effects (SAHA 1000 nM, TSA>300 nM) (Kong, Lin et al. 2006). This is 
consistent with the observation that relatively high concentrations of SAHA or TSA 
have relatively high IC50 on HDAC5 (SAHA 7200 nM, TSA 520 nM (Shi, Scott et al. 
2011). The HDAC5 specific inhibitor LMK235 effectively destabilizes HIF-1α at 
relatively low doses, correlating to its low IC50 on HDAC5 (4.22 nM). Consistent 
with the data from TSA and SAHA, HDAC5 knockdown also induces hydroxylation-
independent, proteasomal degradation of HIF-1α, represses HIF-1 function and 
cancer cell proliferation under hypoxic conditions. It would be interesting to 
investigate whether suppression HDAC5 is sufficient to inhibit the growth and 
progression of hypoxic tumors. 
On the other hand, HDAC5 also regulates HIF-1α in cardiac muscles. My data also 
indicate knockdown of HDAC5, treatment of general HDACI (TSA), or HDAC5 
specific inhibitor LMK235, reduces hypoxia-triggered HIF-1α accumulation in H9c2 
cells, a rat cardiacmyocyte line. HDAC5-HIF-1 pathway may also play an important 
role in cardiac function. Interestingly, HDAC5 knockout mice showed cardiac 
hypertrophy, which may result from a failure of physiological and developmental 
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adaptation to cardiac hypoxia (Chang, McKinsey et al. 2004). Supporting this point, it 
was reported that overexpression of HIF-1α was sufficient to attenuate the cardiac 
hypertrophy caused by HDAC5 knockout (Xue, Cai et al. 2010). Moreover, I have 
observed that hypoxia specifically up-regulates the expression level of HDAC5 but 
not HDAC4 at both mRNA and protein levels, suggesting that HDAC5 is likely to 
play an important role in O2 and metabolic homeostasis in specialized tissues.  
The cytosolic localization of HDAC5 is also triggered by calcium/calmodulin-
dependent protein kinase II (CaMKII) (McKinsey, Zhang et al. 2000). CaMKII is a 
serine/threonine-specific protein kinase activated by the calcium/calmodulin complex, 
which plays an important role in the calcium-mediated signaling pathways. CaMKII 
is important for many cellular functions such as muscle contraction, 
hormone/cytokine secretion, learning and memory (Lisman, Schulman et al. 2002). 
Since HDAC5 is highly expressed in cardiac muscles (Chang, McKinsey et al. 2004) , 
it would be interesting to investigate whether HDAC5 mediates HIF-1α stabilization 
in response to other physiological or metabolic signals involving calcium-mediated 
signaling pathways.  
In conclusion, solid tumors often outgrow blood supply, resulting in insufficient O2 
and glucose supply. Hypoxia and low glucose supply are major pathological 
conditions associated with a variety of ischemic disorders. My novel findings suggest 
a model by which the low energy status facilitates HIF-1α stabilization, activates 
HIF-1 function, and supports cell survival under metabolic stresses.  
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I summarize my novel findings in Figure 9. In this model, HIF-1α is constitutively 
expressed in the cells. Hsp70 recognizes nascent HIF-1α peptides, thus binding to the 
nascent HIF-1α. If Hsp70 is deacetylated, it will pass the nascent HIF-1α peptide to 
Hsp90 complex to complete the folding and maturation process. If Hsp70 is 
hyperacetylated, the nascent HIF-1α peptide will be delivered to proteasome for 
degradation. When cells lack enough blood supply, low glucose and hypoxia activate 
AMPK, which phosphorylates HDAC5 and promotes its cytosolic translocation.  
HDAC5 will deacetylate Hsp70, which allows more nascent HIF-1α peptides to be 
delivered to Hsp90 complex for maturation. Eventually, more matured HIF-1α will be 
accumulated in the nucleus. The increased HIF-1α will enhance HIF-1-dependent 
transactivation, which induces the metabolic adaption and promotes cell survival, 
growth and proliferation under stressful conditions.  
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Figure 9 
 
 
Figure 9 Biological role of HDAC5-mediated HIF-1α stabilization and HIF-1 
activation 
Hypoxia, low glucose or ischemia, activates AMPK pathway, which promotes the 
cytosolic localization of HDAC5. Cytosolic HDAC5 deacetylates Hsp70; and  
deacetylated Hsp70 passes nascent HIF-1α to Hsp90, thus promoting the maturation 
of HIF-1α. 
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Appendices 
1. Abbreviations 
17-AAD               17-allylaminogeldanamycin 
AMPK                  adenosine monophosphate-activated protein kinase 
ARNT                  aryl hydrocarbon receptor nuclear translocator 
ATP                      adenosine triphosphate 
CA-IX                  carbonic anhydrase 9 
Cas                       CRISPR-associated genes 
ChIP                    chromatin immunoprecipitation 
CRISPR               clustered regularly interspaced short palindromic repeats 
DFX                     desferrioxamine 
FIH-1                   factor inhibiting HIF-1 
GAPDH               glyceraldehyde 3-phosphate dehydrogenase 
GLUT1                glucose transporter 1 
HAT                    histone acetyltransferase 
HDAC                 histone deacetylase 
HDACI                histone deacetylase inhibitor 
HIF                      hypoxia-inducible factor 
HK2                         hexokinase 2 
Hsp70                 70 kilodalton heat shock proteins 
Hsp90                 90 kilodalton heat shock proteins 
LDH                    lactate dehydrogenase 
LMB                   leptomycin B 
MEF-2                myocyte enhancer factor-2 
149 
 
MG132               carbobenzoxy-Leu-Leu-leucinal 
ODD                   oxygen-dependent degradation domain 
PAS                   PER-ARNT-SIM 
PER                   period circadian protein 
PFK2                 phosphofructokinase 2 
SIM                   single-minded protein 
TAD                  transactivation domain 
TSA                   trichostatin A 
VEGF                vascular endothelial growth factor 
VHL                  von Hippel-Lindau tumor suppressor 
bFGF                 basic fibroblast growth factor 
bHLH                basic helix-loop-helix 
qRT-PCR          quantitative real-time polymerase chain reaction 
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